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A.1 Riassunto: Interazione tra proteine ed identificazione di 
antagonisti ad alta affinità 
 
Negli ultimi anni la comunità scientifica ed il mondo imprenditoriale 
stanno sinergicamente tentando d’individuare nuove strategie terapeutiche 
che possono riscontrare concrete applicazioni in campo bio-medico e bio-
tecnologico. In questa era post genetica, la proteomica sta offrendo una serie 
interessanti prospettive che inevitabilmente si riflettono nello sviluppo del 
Drug Discovery - Delivery. Infatti, al fine d’identificare nuovi farmaci risulta 
indispensabile individuare inizialmente dei promettenti pathways cellulari ed in 
seguito condurre un’analisi strutturale e funzionale dei fattori proteici coinvolti. 
Patologie come l’infiammazione cronica e la carcinogenesi sono state da 
sempre oggetto di studio ma solo recentemente Michael Karine ha 
confermato l’ipotesi che i fattori trascrizionali NF-κB possano rappresentare il 
vero e proprio legame molecolare tra processo infiammatorio e tumorigenesi. 
Infatti, oltre a coordinare la risposta immunitaria, NF kB riveste un ruolo 
cruciale nella carcinogenesi; in particolare la sua azione promotrice o inibitrice 
dello sviluppo e della progressione tumorale risulta essere cellula –specifica. 
Considerando l’importanza di NF-kB nella risposta immunitaria innata ed 
adattativa, la sua diretta inattivazione può determinare  una grave 
immunodeficienza. Di conseguenza nella definizione di terapie ant- cancro 
non è possibile optare per né un’ inibizione prolungata e sostanziale di NFkB, 
né per un’efficace prevenzione verso le cause che ne determinano la cronica 
attivazione. Infatti un  uso prolungato di medicinali antinfiammatori, atti a 
neutralizzare sia infiammazioni croniche che infezioni microbiche e virali, 
potrebbe determinare una serie di effetti collaterali difficilmente controllabili. 
Per questo motivo, recentemente le vie trasduzionali regolate NF-κB sono 
state  indicate  come potenziali  ed alternativi obiettivi terapeutici  per la 
prevenzione ed il trattamento dei tumori.  
 Questo progetto di ricerca  s’inserisce perfettamente in questa 
prospettiva, infatti il suo obiettivo principale consiste nella selezione di 
molecole in grado di bloccare l’azione anti-apoptotica e pro-oncogenica 
indotta dal fattore trascrizionale NF-κB interferendo nell’interazione tra le 
proteine Gadd45β ed MKK7 .  
L’interesse biotecnologico del progetto è strettamente correlato all’ 
identificazione di  molecole- antagoniste che possano essere utilizzate come 
agenti terapeutici nei processi infiammatori inducenti la crescita e 
progressione delle cellule tumorali.  
Infatti, è noto dalla letteratura che l’interazione  tra la proteina Gadd45β e la 
MAP kinasi MKK7 risulta essere cruciale oltre che nei processi infiammatori 
anche nella chemio-resistenza del cancro. Gadd45β (Growth Arrest and DNA-
Damage-inducible) è una proteina acida di circa 18 KDa espressa in risposta 
ad un ampio spettro di agenti genotossici fattori inducenti stress ossidativi e 
radiazioni ionizzanti. Inoltre è stato dimostrato che l’espressione di Gadd45β 
essendo regolata dal fattore trascrizionale NF-κB, risulta essere correlata ad 
una serie di insulti citotossici quali la sovra-produzione di TNFα e di altre 
citochine. In letteratura è ampiamente descritto il meccanismo molecolare 
mediante il quale Gadd45β promuove e sostiene la fisiologica reazione 
antiapoptotica mediata da NF-κB- in risposta a diversi stimoli di morte 
cellulare. Precisamente Gadd45β esplica la sua azione citoprotettiva 
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interagendo fisicamente con alcuni componenti essenziali della famiglia delle 
MAPKs quali MKK4  e MKK7. Queste due chinasi sono conosciute come i 
diretti attivatori di JNK che è uno dei più importanti ed efficaci mediatori della 
morte cellulare programmata. Recentemente è stato descritto come 
l’interazione tra Gadd45β e MKK7 sia mediata dai domini 60-86 e 103-114 di 
Gadd45β, contenenti molti residui acidi, e dal dominio 132-156 di MKK7, ricco 
in aminoacidi basici, costituenti il sito attivo dell’enzima. L’interazione di 
Gadd45β con la chinasi comporta un mascheramento del residuo di Lys149 
presente nel dominio catalitico di MKK7. Il legame tra le due proteine genera 
una incompatibilità sterica tra Gadd45β ed l’ATP che si concretizza 
nell’inibizione dell’attività chinasica di MKK7. La conseguente soppressione 
della cascata di JNK comporta uno spostamento dell’omeostasi cellulare 
verso un ciclo di sopravvivenza che risulta essere un aspetto cruciale sia 
nell’oncogenesi che nell’infiammazione. Sulla base di queste osservazioni si 
può facilmente delineare  il  ruolo chiave  svolto da Gadd45β nel delicato 
equilibrio tra azione pro-apoptotica del TNFa (ed altre citochine) ed  effetti 
anti-apoptotici del fattore di trascrizione NF-κB. Per tali ragioni l’interazione 
Gadd45β–MKK7 risulta essere un obiettivo di enorme rilevanza terapeutica 
per lo sviluppo di molecole anti-infiammatorie ed anti-tumorali basate sul 
miglioramento dell’attività endogena del TNFa. 
Dal momento che il bionomio struttura-funzione risulta essere essenziale 
per comprendere a livello molecolare i meccanismi cellulari, la prima parte del 
progetto è stata incentrata sulla caratterizzazione di Gadd45β ed MKK7 
utilizzando tecniche bio-molecolari spettroscopiche  e bio-chimiche. 
Inizialmente sono state ottimizzate le condizioni di clonaggio, espressione in 
E. Coli e purificazione delle due proteine in forma ricombinante.  
Una  preliminare caratterizzazione strutturale di MKK7, impiegando 
tecniche di dicroismo circolare, ha confermato che la chinasi mostra una 
conformazione prevalentemente ad α elica con un discreto contributo di β 
sheet. Inoltre le successive analisi mediante cromatografia ad esclusione 
molecolare, hanno permesso di constatare che MKK7 tende a presentarsi 
prevalentemente in forma dimerica. I risultati sperimentali ottenuti sono in 
accordo con i dati riportati in letteratura per MKK7 e per chinasi omologhe. 
 Per quanto concerne Gadd45β e’ stata condotta una dettagliata analisi 
strutturale mirata alla caratterizzazione delle regioni coinvolte nell’auto-
associazione di questa proteina. Le canoniche tecniche biochimiche e 
spettroscopiche hanno inizialmente permesso di constatare che Gadd45β è 
presente in soluzione acquosa sotto forma di un omodimero e che, 
contrariamente all’omologa Gadd45α, Gadd45β non ha una spiccata 
tendenza ad oligomerizzare. La realizzazione di saggi immunologici di tipo 
Elisa ha permesso di determinare una costante di autoassociazione 
nell’ordine di 100 nM e  tale valore è risultato essere in accordo con la 
concentrazione della famiglia delle proteine Gadd stimata nei tessuti cellulari. 
La proteolisi enzimatica della proteina Gadd45β ha consentito di ottenere una 
miscela di frammenti peptidici successivamente purificati e caratterizzati per 
HPLC ed LC-MS/MS, ed impiegati come competitori in un saggio Elisa. Dal 
confronto dei risultati ottenuti con i dati di modeling riportati in letteratura è 
stato possibile identificare nelle eliche putative H1 e H5 le due regioni 
responsabili della autoassociazione di Gadd45β. Si e’ visto come queste due 
eliche interagiscono in maniera non covalente ed antiparallela con le 
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corrispondenti regioni di un’altra unità monomerica determinando la 
formazione una compatta struttura dimerica in grado di interagire 
selettivamente con MKK7. 
Ottenute e caratterizzate le due proteine ricombinanti, e dopo aver 
studiato il complesso che esse formano (MKK7- Gadd45β –Gadd45β –MKK7) 
è stato seguito un approccio combinatoriale allo scopo di individuare un 
antagonista specifico per tale interazione. In particolare la strategia adottata e’ 
stata improntata sulla sintesi di collezioni peptidiche coordinata alla succesiva 
deconvoluzione mediante saggi immunologici. 
Le collezioni di tetrapeptidi sono state disegnate seguendo una struttura 
generale del tipo:  
 
 
 
Fmoc-(βAla)2-Y1-X2-X3-X4-CONH2 
 
 
 
Il gruppo protettore aromatico Fmoc (9-fluorenil-metossi-carbonil) è stato 
inserito all’ N-terminale in modo da facilitare l’utilizzo delle collezioni in saggi 
immunologici e per  eventuali studi di fluorescenza; come spaziatore 
molecolare sono stati utilizzati due amminoacidi β-Alanina; i simboli Y e X 
rappresentano rispettivamente amminoacidi noti e miscele randomizzate. La 
sintesi dei peptidi lineari e’ stata condotta in fase solida (SPPS) applicando la 
tecnica del premiscelamento ed inizialmente sono stati selezionati ed utilizzati 
solo 12 dei 20 amminoacidi naturali. La collezione era costituita da un numero 
teorico di 20736 differenti peptidi (124) in 12 diverse frazioni, ognuna delle 
quali presentava un diverso aminoacido in posizione Y. La libreria è stata 
utilizzata in saggi ELISA di competizione utilizzando la proteina MKK7 
immobilizzata sulla superficie delle piastre (42 nM) e Gadd45β biotinilata (21 
nM) in soluzione. 
La deconvoluzione delle collezioni peptidiche è stata condotta in maniera 
iterativa  seguendo il seguente schema: 
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Questo approccio combinatoriale ha permesso di identificare 
un’antagonista (Lead 1) che è risultato essere in grado di spiazzare 
l’interazione tra Gadd45β ed MKK7 a concentrazioni nano molari  (IC50 di 
circa 1 nM). 
Dopo aver selezionato il peptide Lead 1, la sequenza è stata 
successivamente ottimizzata realizzando una nuova collezione nella quale 
sono stati inseriti i residui amminoacidici esclusi precedentemente. Sono stati 
quindi disegnati e sintetizzati 24 diversi tetrapeptidi privi della porzione Fmoc-
(βAla)2, in modo da incrementarne la solubilità. La deconvoluzione di questa 
collezione di seconda generazione ha permesso di identificare un nuovo 
antagonista dotato di IC50 sub-nanomolare (Lead 2). I due peptidi selezionati 
presentano una serie di notevoli somiglianze sia strutturali che di natura 
chimico-fisica, entrambi conciliando un’elevata efficienza operativa ad una 
notevole solubilità in soluzione acquosa. Tali caratteristiche abbinate agli 
indiscutibili vantaggi della sintesi peptidica contribuiscono a promuovere 
questi tetrapeptidi come candidati ideali per future applicazioni terapeutiche.  
L’integrazione della chimica combinatoriale con le basilari tecniche di 
ingegnerizzazione molecolare ha permesso di migliorare la stabilità nei mezzi 
biologici degli antagonisti selezionati. Infatti sintetizzando tali peptidi come 
retroinversi, sono stati resi immuni alla degradazione proteasica e quindi 
impiegabili in una serie di saggi cellulari essenziali per poter valutare un 
plausibile potenziale terapeutico dei  lead compounds 1 e 2. 
Sono stati allestiti una serie di saggi chinasici utilizzando estratti cellulari di 
293T pre- trattati con TNFα o P/I  in modo da avere MKK7 nella sua forma 
attiva fosforilata;  JNK e Gadd45β sono stati prodotti da batteri in forma 
ricombinante come proteine di fusione della GST. 
In accordo con i riferimenti bibliografici l’attività chinasica di MKK7 è stata 
controllata verificando la fosforilazione del substrato GST-JNK che risultava 
essere completamente inibita dalla presenza di GST-Gadd45β. Il ripristino 
 
Fmoc-(βAla)2-Y1-X2-X3-X4-CONH2             20736 peptidi  (124) 
 
Fmoc-(βAla)2-5-X2-X3-X4-CONH2           1728 peptidi  (123) 
 
Fmoc-(βAla)2-5-12-X3-X4-CONH2             144 peptidi (122) 
 
Fmoc-(βAla)2-5-12-11-X4-CONH2               12 peptidi  (121) 
 
Fmoc-(βAla)2-5-12-11-9-CONH2                1 peptide 
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dell’attività fosforilativa di MKK7 è stato invece verificato utilizzando nei saggi 
chinasici Lead compounds  1 e 2 a concentrazioni nanomolari e sub-
nanomolari.   
I dati ottenuti non solo hanno confermato l’efficienza dei peptidi selezionati ma 
hanno anche evidenziato che gli antagonisti selezionati non determinano 
alcun effetto inibitorio sull’attività chinasica di MKK7.  
Tale risultato è particolarmente incoraggiante se si considerano le numerose 
problematiche relative alla selezione di inibitori attivi nei cicli chinasici. In 
letteratura sono riportati numerosi studi incentrati sulla modulazione 
dell’attività chinasica  ed il loro denominatore comune può essere 
sinteticamente riassunto nell’ espressione provocatoria  “Specific inhibition 
for non-specific effect ” .  
 
 Il paradosso dell’inibizione chinasica risulta essere strettamente 
correlato all’elevato grado di omologia di sequenza riscontrato nella struttura 
dei domini catalitici. Quindi le molecole che modulano l’attività chinasica 
interagendo a livello della tasca dell’ATP non hanno una particolare selettività  
e ciò determina un’aspecifica inattivazione costitutiva del kinoma. Di 
conseguenza l’impiego di antagonisti ATP – competitivi determina una serie di 
effetti collaterali difficilmente controllabili che possono compromettere la 
delicata rete fosforilativa  che è alla base della trasduzione dei segnali 
cellulari (cell- signalling).  
 
L’ utilizzo di una strategia combinatoriale, integrata e validata da mirati 
saggi d’attività’ ha reso possibile l’identificazione due tetrapeptidi in grado di 
destabilizzare l’interazione tra Gadd45β ed MKK7 usati a concentrazioni nano 
e sub nanomolari. Gli antagonisti selezionati oltre a mostrare un’elevata 
efficienza presentano anche una serie di caratteristiche chimiche e 
stereochimiche comparabili a quelle di piccole molecole organiche e per 
questo risultano essere candidati ideali per l’ingegnerizzazione di una futura 
classe di agenti terapeutici  per malattie croniche infiammatorie e proliferative 
come il cancro.  
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A.2 Summary: Interactions between proteins and 
identification of high affinity antagonists 
 
The relationship between the pathological processes of infection, 
inflammation and cancer is correlated to the role of the transcription factor NF-
κB in cellular homeostasis. Therefore studying NF-κB target genes makes it is 
possible to understand the molecular mechanisms of inflammation, of tumor 
growth and progression. 
Gadd45β is one of the anti-apoptotic regulators controlled by NF-κB in 
response to pro-inflammatory stimuli and genotoxic stress exerting its 
functions by interacting with several partners such as MAP kinases  and DNA 
clamp protein. The interaction between Gadd45β and MKK7 has been 
described as a molecular link between the NF-kB cytoprotective effects and 
the suppression of the signaling of JNK, one of the main MKK7 substrates 
that strongly promotes apoptosis. Understanding this complex network of 
interactions and finding effective antagonists is of preeminent importance for 
elucidating the balance between cell death and cell survival and to modulate 
cell homeostasis for therapeutic applications. 
For this reason, this PhD project has been focused on the structural and 
functional characterization of the Gadd45β-MKK7 complex and on the 
identification of compounds able to disrupt this interaction. In fact, developing  
molecules able to block the pro-survival action of NF-κB without significantly 
compromising the innate activation of the immune system is an effective way 
to suppress the proliferative effects induced by Gadd45β expression. 
Biochemical analyses confirmed that Gadd45β exists in solution prevalently 
as a non covalent dimer in a 1:1 stoichiometry. The self-association 
dissociation constant was estimated to be about 100 nM and by limited 
proteolysis we identified the regions of Gadd45β involved in the self-
association as corresponding to the predicted helix 1 (H1) and helix 5 (H5) of 
the protein. The biochemical analysis of Gadd45β-MKK7 complex has been 
investigated and provided a new context for dissecting the structure-activity 
relationship of this interaction which exhibited a KD of about 13 nM. 
To select antagonists of the Gadd45β-MKK7 interaction, a combinatorial 
chemistry approach has been followed. By this process, Lead Compounds 1 
and 2 have been selected from deconvolution of two generations of 
tetrapeptide libraries. These novel antagonists can disrupt very efficiently the 
interaction between Gadd45β and MKK7 at concentrations in the low 
nanomolar range. Further investigations by co-immunoprecipitation and 
kinase assays have confirmed that the measured antagonistic activity 
matches perfectly with the IC50 values from ELISA data.  
Additionally, the results suggest that the selected peptides disrupt the 
interaction between Gadd45β and MKK7 without directly interfering with the 
kinase activity. Indeed several kinase assays have confirmed that both Lead 
Compounds do not block JNK phosphorylation, therefore they do not enter the 
kinase ATP binding site. These results suggest that Lead Peptides 1 and 2 
have the potential of becoming very useful new drug candidates, since the 
selective inhibition of NF-kB downstream targets, such as Gadd45β, could be 
a way to convert inflammation-driven tumor growth into inflammation–induced 
tumor suppression. 
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1.1 Drug discovery and protein-protein interactions 
 
Drug discovery has become a whole interdisciplinary and independent 
field of research and is gaining an increasing attention from pharmaceutical 
industry and academic researchers (1) .  
This is a multi-step process that aims at finding new potential drugs or at 
improving the performances of those already on the market (2).  
Another major task of drug discovery is also the delivery of drugs at the 
right time in a safe and reproducible manner to a specific target organ at the 
required level (3). Disciplines involved in this process include cell biology, 
bioinformatics, organic and protein chemistry, high-throughput automation and 
ultimately functional in vivo studies (3). Therefore discovering new drugs in 
most cases also leads to the elucidation of cellular mechanisms underlying a 
given disease phenotype (4). Understanding the molecular and cellular 
mechanisms regulating a given disease is a major issue for the identification 
of new drugs and the related clinical development and plays a key role for 
reducing the attrition rate and to speed up the process (5). An outstanding 
support to the process of drug discovery is come from the completion of the 
human genomic sequence and by the introduction of novel genomics and 
proteomics technologies. A further contribution has been provided by the 
development of new disciplines, like System Biology, that study the complex 
network of interactions established by a set of proteins and their association 
with pathologies, making predictions of new potential interactions and on 
alterations induced by the down- or up-regulation of a given target protein. 
New challenges are thereby now open and they concern the identification of 
new cellular targets specifically associated with diseases and the 
development of small molecules that can modulate protein–protein 
interactions instead of enzymatic functions (6;7;8). 
   The number of new Therapeutic Strategies based on inhibiting protein-
protein interactions is steadily increasing and it is now estimated that 30-35% 
of the discovery programs deal with interactions between proteins (9). 
However the development of inhibitors of enzyme activity is still a valid 
approach for several viral diseases, for cancer and inflammation and, in this 
field, the selective inhibition of kinases is far the approach of widest interest. 
(10;11). 
This trend is not surprising because protein kinases are the cornerstones of 
many cell signalling systems (12). In fact protein phosphorylation plays a key 
role in the regulation of a diverse range of cellular functions. Especially 
Mitogen Activated Protein Kinases (MAPKs) are involved in different aspects 
of immune response and various pathological conditions (13). This family of 
Ser/Thr protein kinases are activated by a wide spectrum of extracellular 
stimuli. Their activity is usually crucial in inflammation as well as in 
proliferative diseases such as cancer (14). MAPK pathways coordinate gene 
transcription activation, protein synthesis, and all cell cycle. They are 
components of signal transduction that feature a core triple phophorylative 
cascade (15). Furthermore phylogenetic analyses confirm that the basic 
assembly of MAPK pathways in a three–component module is conserved 
from yeast to human (16). These transductional ways can be regulated by 
different sets of stimuli, including growth factors, inflammatory cytokines, 
chemical insults and radiant stresses (17). Duration and degree of kinase 
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activity are influenced by the delicate balance between activating signals and 
inactivating mechanism (18;19). Especially in mammalians, the multiple 
MAPK pathways are often in conjunction with nuclear factors (NK) (20;21;22) 
which are regulative elements of gene transcription. This linker explains how 
the MAPK are pivotal to stress and inflammatory response (17;23;24). 
In figure 2 are schematized the two major groups of MAPKs in mammalian 
cells: 
-  the extracellular signal regulated protein kinases (ERK) (25) 
- the stress activated protein kinase (SAPk) family that includes SAPK-1/JNK 
and SAPK-2/P38 (26;27).   
The relevance of kinase proteins in the modulation of immune response and 
human diseases suggests MAPK inhibitors to be used as anti-inflammatory 
and immunoregulatory molecules (18;26;28). 
 
 
 
 
 
 
   
         
          Fig. 1: Organization of mammalian MAPK kinase. The MAPK cascade 
consist of a series of three protein kinases: a MAPK and two upstream components, 
MAPK kinase (MAPKK) and MAPKK kinase (MAPKKKs). These last are often 
component of more than one signalling pathways as presented here. MAPKs can 
phosporylate transcriptional target directly or through downstream protein kinases. 
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1.2 Protein Kinases in Drug discovery and 
Development 
 
The MAPKs have a “master-switch” function in balancing between cell 
proliferation and programmed cell death, controlling cellular architecture and 
polarity (13). These enzymes regulate multiple cellular processes that 
contribute to tumour development and progression, including cell growth, 
differentiation, migration, and apoptosis (29;30). 
Extensive efforts have been made to develop kinase-specific inhibitors to treat 
diseases caused by the deregulation of signalling pathways (10;31), but this 
goal, because of the large structure similarity between all components of the 
family, especially at the level of the kinase domain, is a very challenging task 
(32). In addition, given the complexity of MAPK signal-transduction networks, 
the criteria that qualify a particular kinase as a putative drug-target are not 
straightforward (33;34). 
Ten years ago only seven kinase inhibitors were under clinical evaluation, 
instead today they are more than 400 from early pre-clinical to marketed 
drugs in cancer treatment (35;36). Among the various approaches for the 
modulation of protein kinase activity, the inhibition by low-molecular-weight 
compounds appears to be the most interesting (29;37). Nevertheless, this 
kind of highly selective small-molecule inhibitors frequently presents problems 
of selectivity. In fact the vast majority of these compounds bind the hot spot of 
kinase domains: the ATP pocket (38). Considering that the catalytic kinase 
site is the most conserved in sequence and structure, the ATP competitive 
inhibitors show obviously a multi activity against human kinome (16). 
Significant is the case of SP 600125 selected as a direct JNK inhibitor. This 
anthrapyrazole was identified in a screening of chemical library (39) and it has 
been successively evaluated in animal models for arthritis rheumatoid 
showing anti-inflammatory effects (40). Subsequent assays against a broad 
range of kinases confirmed that SP 600125 inhibited 20 of the 30 kinases 
tested. As a consequence, the in vivo results previously obtained present an 
ambiguous interpretation (41). This example can explain why despite a 
significant quantity of disease-associated protein kinases, only a limited 
number of kinases have been successfully targeted.  
The paradigm of inhibiting a specific kinase pathway can be extensively 
explored identifying new drug targets (42). 
In fact the kinase inhibition or activation is often mediated by physical 
interaction with proteins up-regulated from transcriptional factors (12;43-46). 
Therefore these pivotal mediators could be more desirable targets for 
inflammatory and anti cancer therapy (47) and their characterization and 
validation as targets could open the way to new Therapeutic Strategies based 
on modulating interactions between proteins instead of blocking highly 
conserved enzymes. 
 
 
 
 
 
 
 11 
1.3 Gadd45 Family: Key proteins of cell signalling   
 
Gadd45 proteins have such highly regulative properties and it is widely 
accepted that that they are implicated in cell signalling at several levels (47). 
The gadd45 growth arrest and DNA damage-inducible family of genes, 
comprising gadd45a, gadd45b and gadd45g, encode for the corresponding 
Gadd45α, Gadd45β and Gadd45γ acidic proteins of about 18 kDa. They are 
ubiquitously expressed and exert the primary function of growth arrest and 
apoptosis induction in response to several genotoxic stresses thus 
contributing to cellular homeostasis (44;47-51).  
Numerous studies confirm the pivotal role of Gadd45 family in a variety of cell 
functions such as DNA replication and repair (52), cell cycle regulation (53) 
and, depending on cell type and cell metabolic state, also in cell survival (50). 
However, in literature there is no reported enzymatic activity for Gadd45 
proteins. Then the members of Gadd45 family are significant examples of 
key-proteins exerting their biological functions by interaction with several 
protein partners.  Indeed, highly specific interactions with PCNA 
(44;48;52;54;55) cdc2 (48) waf/p21 (44;48;56;57) cdk1/cyclinB1(44), 
MEKK4(58) and CRIF1(59) are involved in Gadd45 regulation of the cell cycle 
and the response to external cell stimuli. 
 
 
 
1.4 Gadd45β in the cell system: functional - structural 
characterization 
 
Gadd45β is one of the most important member of Gadd45 family (48) ; it 
has been described as an NF-kB –inducible gene and as a prominent 
mediator of NF-KB protective response to TNF-α and UV-induced apoptosis 
(43;15-60). However this aspect is still controversial and several reports 
indicate Gadd45β as an effective pro-apoptotic factor, too (47;51;52). The 
mechanisms by which Gadd45β can promote cell survival have been 
extensively investigated and it has been found that in MEFs and other cells, 
upon NF-kB induction, it provides selective JNK inactivation by inhibition of 
the upstream MKK7 kinase (19;43;61;50)  (Fig 3). In hematopoietic cells, 
instead, it blocks JNK activation by binding to MKK4 (48;50), and in B cells it 
is a critical mediator of the pro-survival activity of CD40 elicited in response to 
Fas stimulation (63).  
The primary sequences of Gadd45 proteins share an overall 70% homology 
(about 60% identity, See Fig. 2A e 2B ) and all contain six cysteines, five of 
which (from the 2nd to the 6th) are located in highly conserved positions. 
Importantly, it has been reported that Gadd45 proteins are also able to homo- 
and hetero-dimerize or oligomerize (64).  
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Fig.2A: Alignment of Gadd45α, β and γ sequences. An identity of about 60% is 
observed. Most differences are present in the region corresponding to the second 
acidic loop, with a Gadd45g pentapeptide stretch remaining unpaired with the other 
two sequences. To correctly align the Gadd45α variant, an 8-residue long stretch is 
required. Within the acidic loop (61), residues Asp67 of Gadd45β is mutated to Arg in 
the α variant and to Gly in Gadd45g. Regions involved in self-association are 
underlined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2Β: Representation of the protein secondary structure is schematized 
based on the model described in reference (61). 
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1.5 Gadd45β and MKK7: a potential target for anti-
cancer and anti – inflammatory therapies 
 
The coordination between immune and inflammatory responses is correlated 
to the activation of the NF-κB/Rel transcription factors. As a consequence, 
they control cell survival (43). Activation of NF-KB antagonizes apoptosis or 
programmed cell death by numerous triggers, including the ligand 
engagement of death receptors, such as tumour-necrosis factor (TNF) 
receptor or TRAIL (20). The anti-apoptotic activity of NF-kB is also crucial to 
oncogenesis and to chemo- and radio-resistance in cancer (23). 
Cytoprotection by NF-kB involves the activation of pro-survival genes which 
down regulates the c-Jun amino terminal kinase (JNK) cascade (75) (Fig.3). 
It has widely been described how Gadd45β mediates the NF-kB suppression 
of JNK signalling by physically interacting with MKK7 (47). 
Then  Gadd45β – MKK7 interaction is a molecular crosslink between the anti-
apoptotic activity of NF-kB and the suppression of the JNK cascade, thereby it 
acts as a key checkpoint to control cell fate downstream of TNF-Rs 
(19;61;47).  
The structural basis of this interaction has been extensively described in 
literature (19;47;61;68). Gadd45β associates with MKK7 through an extensive 
network of interaction mediated by residues comprised within its putative a3, 
loop 1 and a4-loop 2 regions. The model proposed in the paper by Papa et al, 
explains the structural basis of Gadd45β-mediated inactivation of MMK7. The 
complex Gadd45β-MKK7 is stabilized by electrostatic interaction and H–
bonds formed between charge/polar residues positioned at the interface 
between the two proteins and Gadd45β inactivates MKK7 by masking critical 
residues, such as the Lys149 required for ATP binding, causing 
conformational changes that impede the proper catalytic kinase function (Fig 
4). This molecular scenario is further complicated by the presence of multiple 
equilibriums of self-association between Gadd45β and MKK7 monomers, as 
both reportedly have at least a dimeric structure. The occurrence of such 
homo-oligomeric forms could be a regulative element of the interaction 
between the two proteins and their effects need additional investigations.  
The suppression of JNK signalling dependent on NF-kB activity is a constant 
in chronic inflammatory conditions such as rheumatoid arthritis and 
inflammatory bowel disease and several malignancies (65). Therefore the 
interaction between Gadd45β and MKK7 can be indicated as a potential 
therapeutic target and identifying compounds that disrupt this binding can 
represent a valid approach for the treatment of several diseases, such as 
cancer and inflammation. If provided with a sufficient selectivity, they can be 
potent therapeutic agents with a novel mechanism of action, whereby the 
effects of NF-kB activation are largely impaired without suppressing the 
physiological JNK signalling.  
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Fig. 3: TNFR1-induced pathways modulating apoptosis. Formation of complex I 
lead to NF- B activation, Gadd45ß induction, JNK inhibition and cell survival. 
Usually, ubiquitous NF- B dimers are sequestered in the cytoplasm by inhibitory I B 
proteins (I B , I Bß and I B ).  Stimulation by TNFα induces a sequential 
phosphorylation and subsequently proteolysis of I Bs, but after removal of the 
inhibitors, NF- B dimers enter nuclei to induce expression of coordinated sets of 
target genes that regulate innate and adaptive immunity, inflammation, cell growth 
and cell survival. Gadd45β expression is up-regulated by TNF and mediated by NF-
kB. Gadd45β strongly interacts with MKK7, an upstream JNK activator, inhibiting its 
kinase activity. 
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Fig. 4: Model of the Gadd45β -MKK7 complex represented in ribbon   by MD 
simulation: MKK7 is in light blue and Gadd45β is in pink (A). Interface of interaction: 
basic residues of MKK7 are in blue instead the acidic residues of Gadd45β are in 
red; 60–114 region is reported in magenta and H-bonds are depicted as green dotted 
lines (B). Detail of H-bond (green) between Asp166 and Lys149 (C). 
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1.6 Bio-molecular Engineering and Combinatorial 
Design: two alternative approaches in drug discovery 
 
The introduction of new pharmaceuticals is a lengthy and very expensive 
process (fig.5) that, starting from a given medical need, proceeds through the 
identification of validated targets, the selection of chemical leads and the 
identification of drug candidates that are subsequently developed in the 
preclinical (toxicology) and the clinical phases. the several phases of 
development  (5). The original strategy, based on the random screening of 
proprietary compound collections and of plant extracts has been gradually 
supersede by the introduction of powerful design techniques (favoured by the 
advent of the structural biology) and of combinatorial chemistry and High 
Throughput technologies. The primary objective of the combinatorial 
chemistry is the generation of random or focused libraries composed of large 
numbers of molecules that are successively screened (66) to identify new 
leads. Random peptide libraries have been largely employed in the past 
decade for the rapid identification of new leads that have then converted into 
small molecules endowed with improved pharmacological and stability 
profiles. They offer the great advantage of being easily prepared and 
screened and, due the very robust synthesis procedures, can be used in 
mixture-based formats (67). Active peptides can be isolated by these mixtures 
and identified following different deconvolution strategies (68). However, 
peptides generally do not fulfil the requirements of low conformational 
flexibility, stability and bioavailability needed for good drug candidates and 
peptide “leads” with high potency and selectivity are often made “druggable” 
by conversion to more stable structures with improved pharmacological 
profiles. This approach makes the screening of peptide libraries still a 
valuable tool for drug discovery (69), though it has been integrated with 
techniques of rational design, in silico screening and biomolecular engineering 
to facilitate the transition from peptides to useful drug candidates (6).  
 
 
 
1.7 Therapeutic Peptides: interesting perspectives in 
Medicinal chemistry 
 
The therapeutic application of peptides have has often hampered by their lack 
of in vivo stability and poor biodistribution and delivery properties. Due to 
protease degradation, the half-life of peptides is extremely short and they are 
typically cleared from bloodstream after few hours from administration. In 
addition they cannot cross cell membranes, therefore, even peptides with high 
potency in vitro do not show effects in vivo because their exposure to the 
target tissue is insufficient (70). Despite their poor bioavailability properties, 
the premise of transforming peptides into good therapeutics still holds. Indeed 
they offer several advantages over small molecules and proteins (71), 
especially to antagonize protein-protein interactions. For example, they have 
large recognition surfaces that can match better with the large interfaces 
underlining protein-protein contact regions; in addition their flexibility provides 
them with higher affinities and specificity for the targets. Peptides also have 
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low toxicity profiles and, differently from proteins, also exhibit higher stability 
at room temperature and higher tissue penetration (70). The therapeutic 
properties of bioactive peptides can be improved by several techniques that 
include the incorporation of D-amino acids (72) and cyclization (73), which 
can increase proteolytic stability and improve the conformational flexibility 
which are fundamental prerequisites for getting optimal lead compounds. 
 
 
1.8 Aim of the project 
 
The aim of this research project was twofold. In a first part of the work we 
wanted to study the oligomeric assembly of the proteins Gadd45β and MKK7 
and their relevance in the mechanism of inactivation of the kinase by 
Gadd45β. Indeed, as both proteins are known to oligomerize or dimerize, this 
event could be a regulative mechanism of the interaction. This goal has been 
pursued by first studying the oligomerization status of the proteins and by next 
defining the regions of self-interaction on Gadd45β. Using a combination of 
biochemical and spectroscopical techniques, the secondary structure 
elements participating in self-association will be identified and correlated to 
the known structural elements mediating the interaction with MKK7. 
Identification of Gadd45β fragments involved in self-association will be 
performed using a method of protein digestion, peptide fractionation by HPLC 
and competitive ELISA assays. 
In a second phase of the project, we will develop peptide antagonists of the 
interaction between Gadd45β and MKK7. This goal will be pursued by 
performing a screening of combinatorial peptide libraries made of synthetic 
tetrapeptides. The screening will be carried out utilizing an ELISA-like assay 
on a library built in a simplified format, whereby only 12 out 20 natural 
aminoacids will be used. The advantage of using tetrapeptides relies on the 
easiness of preparation and the rapidity of screening. Furthermore, short 
peptides with only few residues have structural properties more similar to 
small molecules to which they can be easily converted. The synthesis of the 
library will be performed following the Mix-and-Split method that leads to 
combinatorial mixtures. The screening will be carried out by a competitive 
ELISA assay. The selected peptides will be next engineered to possibly 
improve the affinity and increase the peptide stability toward a set of 
proteases. Finally the peptides will be submitted to cell assays to assess the 
efficacy also in a more physiological environment and verify that the 
antagonists only block the interaction, without affecting the kinase activity.  
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Fig 5:  The diagram illustrates the early phase of drug discovery in 
which the aim is to identify target and lead molecules. Instead of 
isolated problems, drug discovery incorporates a whole series of 
challenges spanning from the biological problem of characterising a 
disease on a molecular level, to finally bringing a drug to the market. 
While Bioinformatics approaches deal mostly with the early stages of 
target selection and structure identification, Cheminformatics addresses 
the later stage problems like lead identification and lead optimization.  
Source: Nat Rev Drug Discov. 2007 Nov;6(11):891-903. 
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2.1 Cloning expression and purification of 
recombinant protein  
 
2.1.1 Cloning  
 
hGadd45b and hMKK7 were PCR amplified using the oligonucleotides 
reported in table 1, then double digested with proper restriction enzymes (see 
table 1). Digested fragments were extracted from 0.8% agarose gel using 
QIAquick Gel Extraction Kit and cloned into pGEX6P-1 vector, previously 
digested and dephosphorylated. Ligation products were electroporated into 
TOP10F’ cells and recombinant colonies were isolated using QIAprep Spin 
Miniprep kit according to the manufacturer’s instructions. 
These clonings  allowed the expression of the proteins of interest as GST-
fusion products containing a highly specific cleavage site for PreScission 
Protease upstream the protein sequence. 
 
 
 
Table 1: Cloning conditions 
 
 
Samples Oligonucleotides Enzime 
restriction 
3’ CGC GCG CCA TGG GCA TGA CGC TGG 
AAG AGC TCG TGG 5’ 
NcoI GST 
hGadd45β 
 
5’ CGC GCG CTCGAG TTA CTA GCG TTC 
CTG AAG AGA TGA TGG 3’ 
                                                    *      * 
XhoI 
3’ CGC GCG GGATCC ATG GCG GCG TCC 
TCC CTG GAA CAG 5’ 
BAMHI  
GST 
hMKK7 
 
3’ CGC GCG  CTC GAG TTA CTA CTT CTT 
CGC CAT GAC ATC CTT GAA CCA 5’ 
                                             *      * 
XhoI 
 Enzyme site = underlined 
 * = stop codon 
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2.1.2 Expression  
 
The expression of recombinant proteins: hGadd45β, hMKK7 and hJNK were 
induced by treatment for 16h of BL21(DE3)trxB bacterial strain with  0.1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) at 22 °C.  In every  case a 200 mL 
pellet was re-suspended in 20 mL of cold lysis buffer (see table 2) 
supplemented with protease inhibitor mixture (1 mM PMSF, 1.0 µg/mL of 
aprotinin, 1.0 µg/mL of leupeptin, 1.0 µg/mL of pepstatin, and 1.0 mg/mL of 
lysozyme) and incubated at room temperature for 30 min. Cells were 
disrupted by sonication on ice with 10 s on/10 s off cycles for a total of 10 min 
on. After centrifugation at 15,000 rpm for 30 min at 4 °C, the supernatant was 
opportunely purified on an ÅKTA FPLC chromatography system using either 
HisTrap HP or GSTrapFF (GE Healthcare) columns. Column were washed 
with lysis buffer without Triton and inhibitors. The elution of the proteins was 
carried out using proper buffers (see table 2) and monitored by measuring 
absorbance at 280 nm. The resulting fractions were analyzed by 15% SDS-
PAGE. The eluted fractions were dialyzed against opportune buffers as 
requested in the next analysis or purification steps. 
To try to carry out accurate structural characterization of hGadd45β and  
hMKK7, aliquots of the fusion proteins were digested with PreScission 
protease (GE Healthcare) to remove the GST protein (see table 3). 
After tag removal, proteins were submitted to other purification steps (MonoQ 
and gel-filtration, see table 2) in order to obtain highly purified material (95-
98% pure). 
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Table 2: Purification Buffers 
 
Samples 
 
Type of 
Purification 
Loading  
Buffer 
Elution Buffer 
His6- hGadd45β His trapHP 25 mM Tris, 500 
mM NaCl,10mM 
Imidazole, 1 mM 
DTT, 0.05% (v/v) 
Triton X-100, pH 7.5 
Gradient of 10mM–
500mM imidazole. 
GST hGadd45β 
 
GSTrap FF 20 mM Tris-HCl [pH 
7.0], 100 mM NaCl, 
100 µM PMSF, 1.0 
mM EDTA 
50mM Tris pH 8.0 
10mM GSH 
GST hMKK7 
 
GSTrap FF 20 mM Tris-HCl [pH 
7.0], 100 mM NaCl, 
100 µM PMSF, 1.0 
mM EDTA 
50mM Tris pH 8.0 
10mM GSH 
GST hJNK 
 
GSTrap FF PBS 50mM Tris pH 8.0 
10mM GSH 
hGadd45β MonoQ HR 5/5 
column 
20 mM Tris-HCl [pH 
7.0], 100 mM NaCl, 
100 µM PMSF, 1.0 
mM EDTA 
Step gradient 20, 
40, 60, 80, 100% of 
20 mM Tris-HCl [pH 
7.0], 500 mM NaCl, 
100 µM PMSF, 
1.0 mM EDTA 
hGadd45β – 
hMkk7 
Superdex 75 10/30 20 mM Tris-HCl (pH 
7.0) 150 mM NaCl , 
1mM EDTA and 
with or without 1mM 
DTT 
 
 
- 
 
 
Table 3: Digestion conditions  
 
 
Samples Cleavage 
Buffer 
Units of 
PreScission 
Protease 
Time 
 
GST hGadd45β 
 
50U 6°C for 4 hrs 50 mM Tris-HCl 
[pH 7.0], 100 
mM NaCl, 1.0 
mM EDTA 1mM 
DTT 
GST hMKK7 
 
160 U 4°C for 5 days 50 mM Tris-HCl 
[pH 7.0], 100 
mM NaCl, 1.0 
mM EDTA 1mM 
DTT 
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2.2 Peptides synthesis and purification 
 
Peptides corresponding to different regions of Gadd45β and MKK7  (see table 
4)  were designed on the basis of a predicted model (61) and prepared by 
solid-phase synthesis as C-terminally amidated and N-terminally acetylated 
derivatives following standard Fmoc chemistry protocols. A Rink-amide MBHA 
resin (substitution 1.1 mmol/g) and amino acid derivatives with standard 
protections were used in all syntheses. Cleavage from the solid support, 
performed by treatment with a TFA/triisopropylsilane (TIS)/water (90:5:5, by 
vol.) mixture for 90 min at room temperature, afforded the crude peptides that 
were precipitated in cold ether, dissolved in a water/acetonitrile (1:1, v/v) 
mixture and lyophilised. Products were purified by RP-HPLC using a C18 
Jupiter column (50 mm × 22 mm) applying a linear gradient acetonitrile 0.1% 
TFA between 5% and 70% over 30 minutes. Peptide purity and integrity were 
confirmed by LC-MS mass measurements using a Surveyor LC system 
coupled to an LCQ Deca XP mass spectrometer equipped with an OPTON 
ESI source. The peptide corresponding to fragment G132-N156 of MKK7 (61) 
and the shortest region of Gadd45β still able to bind and block MKK (47) were 
also prepared and purified. The highly acidic peptide Gadd45β (A60-D86) was 
purified by RP-HPLC using a C18 Jupiter column (50 mm × 22 mm) applying 
a linear gradient of acetonitrile from 5% to 70% over 30 minutes, using 10 mM 
phosphate buffer pH 7.0 as eluent A. 
 
 
 
Table 4: Synthetic peptides corresponding the different 
Gadd45b helices 
 
 
Synthetic 
Peptides 
Sequence Molecular 
Weight 
(Da) 
eHelix 1 (A12-
R32), eH1 
Ac-AAQKMQTVTAAVEELLVAAQRQDR-NH2 2669.3 ±0.2  
eHelix 4 (R91-
E104), eH4 
Ac-RVSGMQRLAQLLGE-NH2 1343.6±0.3  
eHelix 5 (A129-
N148), eH5 
Ac-AWKSHGLVEVASYCEESRGN-NH2 2262.6±0.3  
hGadd45β 
(A60-D86) 
Ac-AIDEEEEDDIALQIHFTLIQSFCCDN-NH2 3166.4±0.5 
hMKK7 (G132-
N156) 
Fmoc-
(βAla)2GPVWKMRFRKTGHVIAVKQMRRSGN-
NH2 
3335.5±0.4  
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2.3 Digestion with trypsin and peptide fractionation 
 
An aliquot of Gadd45β (1.0 mg; 0.052 µmol) was dissolved in 2.0 mL of 
50 mM Tris, 20 mM CaCl2, pH 8.0. TPCK-treated trypsin (Sigma) was added 
at a final enzyme-substrate ratio of 1:100 and the reaction kept at 37 °C with 
gentle agitation for 16 h. A protein sample (0.4 µg) was then analyzed by LC-
MS/MS to assess protein digestion using a BioBasic 30 mm × 2 mm ID C18 
column. The column was equilibrated at 200 µL/min with 5% CH3CN, 0.05% 
trifluoroacetic acid (TFA), then a gradient of CH3CN from 5% to 55% over 
65 min was applied and monitored by both photodiode array and MS. The MS 
analysis was conducted by alternatively recording full mass spectra and data-
dependent mass analysis to obtain sequence information from peptide 
fragmentation. The remaining digested protein sample was finally injected on 
a 250 mm × 4.6 mm ID C18 column equilibrated at 1.5 mL/min flow-rate with 
5% CH3CN, 0.1%TFA, applying a 5%–55% gradient of CH3CN over 65 min to 
elute the peptides; 13 fractions of 5 min each were collected from time zero to 
time 65 min, and were analyzed (4 µL) by LC-MS/MS as reported. Lyophilised 
fractions were stored at −80 °C. 
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2.4 Spectroscopic characterization of hGadd45β and 
hMKK7 
 
2.4.1 CD analysis of native proteins 
 
CD spectra were recorded using a Jasco J-810 spectropolarimeter (JASCO 
Corp) equipped with a Peltier-type temperature control system. Spectra were 
recorded in the wavelength range between 195 and 250 nm, at a scanning 
speed of 20 nm/min, a band width of 2 nm, and a temperature of 20°C, under 
constant N2 flow. The recorded spectra were then signal-averaged over at 
least three scans, and the baseline was corrected by subtracting the spectrum 
obtained with sample buffer. The value of molar ellipticity per mean residue 
[θ], expressed in degxcm2xdmol-1, was finally calculated using the following 
equation: [θ] = [θ]obs mrw/10.l.C, where [θ]obs is the ellipticity measured in 
millidegrees, mrw is the mean MW of the residues of the protein, C is the 
protein concentration in g/L, and l is the optical path length of the cell used, 
expressed in cm. The protein concentration to be used for acquisition of the 
CD spectra was optimized in preliminary acquisitions. hGadd45β and hMKK7 
were analysed at a concentration of 5.5 x 10-5 M in water in order to minimize 
salt interference in the far UV region 
 
2.4.2 Gadd45β Stability against Chemical Denaturants 
 
CD spectra were recorded as previously described, native Gadd45β was 
diluted with water to obtain a final concentration of 5.5 × 10−5 M. A blank run 
was carried out before every experiment and subtracted from the protein CD 
spectra. Chemically induced denaturation was carried out on native Gadd45β 
performing 1 degree.(°C) increment every 2 min from  20 °C to 80 °C, 
monitoring the CD signal at 222 nm. The temperature was returned to 20 °C 
to investigate the refolding capacity of the thermally denatured protein. CD 
spectra were again collected after each 2 degrees (°C) change. To investigate 
the effects of concentration on protein oligomerization, serially diluted 
solutions at concentrations ranging from 5.5 × 10−5 M to 5.5 × 10−6 M were 
analyzed using cuvettes with increasing path-lengths in order to compensate 
the signal loss due to dilution. Chemical denaturation experiments were 
carried out evaluating the effect of urea and GdnHCl on Gadd45β 
denaturation as described (74). Briefly, pH-controlled solutions with different 
concentrations of urea and GdnHCl, with protein at a constant concentration 
of 5.5 × 10−5 M were prepared and incubated for 16 h at 20 °C. C hemically 
induced denaturation was monitored by recording the CD value at 222 nm for 
each sample. The reversibility of the denaturation was controlled after 
removal of denaturants from the unfolded protein sample by dialysis 
overnight. The capacity of the recovered protein to recognise MKK7 was also 
evaluated by direct ELISA binding. Corresponding blanks were always 
recorded and subtracted. CD spectra were registered at 25 °C. CD analysis 
was also done on the synthetic peptides used in the ELISA assays. The 
concentration of peptides was kept at 1.0 × 10−5 M and a 0.1 cm path-length 
quartz cuvette was used. Spectra were acquired in a 10 mM sodium 
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phosphate buffer at pH 7.0 and in the presence of increasing concentrations 
of TFE, up to 20% (v/v). 
 
 
2.5 Characterization of Gadd45β structure by 
hydrodynamic methods and LC-MS. 
 
 
2.5.1 Native gels 
 
Laemmli discontinuous system without SDS was used for native gel 
separations. Mobilities of proteins were determined in 8, 10, 12, and 15% gels 
by loading 18 µg of pure proteins from a 1.8 mg/mL solution (100 µM). 
Relative electrophoretic mobilities were calculated relative to the mobility of 
bromphenol blue. Calibration curves were obtained and molecular masses 
calculated according to Sigma protocol (technical bulletin No. MKR-137). 
 
 
 
2.5.2 Size exclusion chromatography  
 
Size exclusion chromatography was used as a final step in the purification of 
Gadd45β and to determine the oligomeric state of the protein To this purpose 
5.0 µM solutions were subjected to gel-filtration chromatography on a 
Superdex 75 10/30 (Amersham Pharmacia Biotech) column equilibrated with 
the buffers shown in the table 2. For calibration, molecular mass markers for 
gel-filtration chromatography were run on the column under the same 
conditions in duplicate. Elution of dextran blue was used to determine the void 
volume of the column. Elution volumes and partition coefficients of the 
standards and samples were calculated according to Amersham Pharmacia 
Biotech protocol. 
 
2.5.3 LC-MS 
 
To further characterize protein purity and MW, we performed LC-MS analyses 
using 5 µl of a 0.1 mg/ml sample and a LCQ DCA XP Ion Trap mass 
spectrometer (ThermoElectron, Milan, Italy). This was equipped with an 
OPTON ESI source (operating at a needle voltage of 4.2 kV and a 
temperature of 320°C) and a complete Surveyor HPLC system (including a 
MS pump, an autosampler and a photo diode array [PDA]). Analyses were 
performed using a 300 Å narrow bore 250x2 mm C4 Jupiter column 
(Phenomenex, Torrance, CA) and applying a gradient of solvent B (0.05% 
TFA in CH3CN) on solvent A (0.08% TFA in H2O) from 30% to 70%, over a 
period of 40 min. During this time, the sample tray was kept at either 4 or 
20°C, whereas the column was kept at 25°C. Mass spe ctra were recorded 
continuously in the mass interval 400-2000 amu, in positive mode (LC-MS, 
condition 1). Multicharge spectra were then deconvoluted using the BioMass 
program implemented in the Bioworks 3.1 package provided by the 
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manufacturer. Mass calibration was performed automatically by means of 
selected multiple charged ions, in the presence of a calibrant (UltraMark; 
ThermoElectron, Milan). All masses were reported as average values. 
 
2.5.4 Protein alkylation assays 
 
For an assessment of the presence of free cysteines, 50 µg of purified native 
Gadd45β (2 mg/ml) was denatured in 50 µl of a solution containing 250 mM 
Tris-HCl (pH 8.5), 1.0 mM EDTA, and 6 M guanidinium chloride for 30 min at 
45°C, in the absence of any reducing agent. The pro tein was then subjected 
to alkylation by incubation of the sample mix to 0.12 M 4-vynil-pyridine (4-VP) 
(Sigma-Aldrich) at 25°C for 60 min, after which tim e the reaction was 
terminated by quenching at 4°C with DTT. Finally, a lkylation was assessed 
using LC-MS. For experiments of limited alkylation, preliminary assays were 
carried out using 6 µg of purified hGadd45β and 0.1 M 4-VP and performing 
incubations in 50 µl of 50 mM Tris.HCl, pH 7.5, at room temperature. 
Alkylation kinetics were monitored by LC-MS at 0, 10, 40, 70 and 90 min, 
using LC-MS, upon quenching the reactions by cooling at 4°C. Optimal 
conditions were identified (i.e. reaction time 10 min, room temperature), and 
free 4-VP was removed by filtration on Vivaspin concentrators with a 5-kDa 
cut-off at 4°C.   
 
 
 
2.6 Combinatorial tetrapeptides library: synthesis and 
iterative deconvolution  
 
The peptide library and single peptides were prepared using all commercially 
available L-α amino acids (listed in Table 5). All residues were 9-
Fluorenylmethoxycarbonyl (Fmoc)-derivatized (>99%) and were utilized 
without any further purification. The library was chemically synthesized 
following the Fmoc methodology and sequence randomization was achieved 
by applying the Mix-and-Split method which therefore required an iterative 
selection and enhancement process to identify lead peptides. See also Fig. A 
and B for schematic examples of the Mix-and-Split process and of the iterative 
screening processes. The tetrapeptide library was generated using a 
simplified peptide library (67) where only 12 out 20 natural aminoacids were 
utilized in order to simplify the synthesis and screening process and, at the 
same time, to take into account the chemical complexity of the side chains 
functional groups and to eliminate several “quasi-duplicates”. Indeed, the 
synthesis of random combinatorial libraries of peptides generates large 
numbers of “quasi-duplicates” deriving from the strong similarity between 
several side chains. Using natural amino acids, in L- or D- configuration, 
sequences where Glu is replaced by Asp, Leu by Ile or Val, Gln by Asn and 
so on, can display very similar properties. Such residues, although being 
different in their propensity to adopt secondary structures, they can be 
considered almost equivalent in terms of intrinsic physical-chemical 
properties, as for example the capacity to establish external interactions or to 
fit in a given recognition site. Thereby, in preliminary screenings, a selection 
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of non-overlapping structures can be chosen, which are subsequently 
optimized introducing the excluded residues. The list of selected amino acids 
used for our study is reported in Table 5, along with a description of chemical 
and physical properties of the single residue. The first generation library was 
thus composed of 20736 peptides (all combinations of 12 amino acids at four 
positions: 124=20736). Twelve mixtures were generated such that the first 
position was individually defined with 12 amino acids and each mixture 
contained the 1728 different tetrapeptides beginning with the particular amino 
acid (Y1XXX-NH2, “Y” represents a single amino acid, while “X” represents all 
the 12 amino acids). The iterative process was carried out re-preparing the 
most active mixture identified. Each of the X positions from Y1XXX-NH2, were 
successively defined with each of the 12 amino acids (i.e., Y1XXX-NH2   
A1Y2XX-NH2 A1B2Y3X-NH2  A1B2C3Y4-NH2 A1B2C3D4-NH2,: the letter A, 
B,C and D represent the identified
 
position). The most active sequence(s) in 
this process was thus identified by the systematic reduction in the number of 
compounds in the most active mixture 1728144121. Three additional 
syntheses were required for each active mixture identified in the original 
library. The next step was to synthesize a library of II generation where the 
excluded aminoacids were introduced, thus arriving at the choice of a series 
of 24 single compounds. The particular library prepared and used in our 
study, had the following general formula: 
 
 
 
Fmoc-(βAla)2-X1-X2-X3-X4-CONH2 
 
 
 
The Fmoc group was introduced in order to have a large hydrophobic and 
fluorescent probe helpful in screening assays. The two β alanines were 
instead introduced as spacer between the library structure and the Fmoc 
group CONH2 represents an amide group at the C-terminus. 
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Fig. A. Mix and Split method for the generation of combinatorial libraries of 
peptides. The method is exemplified for the synthesis of tripeptide libraries with 3 
different amino acids using a resin batch of 270000 resin beads. By this method, 
repetitive cycles of resin mixing and re-pooling are performed until the requested 
length and complexity are reached. The resin beads are distributed in 3 equal 
aliquots of 90.000 beads, then single residues are coupled (Ala, Val, Lys). After the 
washing and deprotection steps, the three aliquots are pooled and carefully mixed. 
By repeating this procedure for N times, a complexity of 3N is achieved. In this 
example, after three randomization rounds, three peptide pools, each with 9 different 
sequences, are generated. In an ideal synthesis, each sequence is present on 
10.000 beads, thus accounts for 10 µmoles of the starting 270 µmoles. 
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Fig. B. Schematic representation of the deconvolution of peptide libraries by 
an iterative screening approach.. The screening of a tripeptide library with 20 
different building blocks is exemplified. In the first screening round 8000 compounds 
arranged in 20 pools of 400 peptides each is submitted to a screening assay, 
whereby a single 400-components pool is selected. In the second screening round, 
the selected 400 peptides present in the selected pool, are re-synthesized in a format 
where 20 sub-pools of 20 molecules each are arranged. A 20-components sub-pool 
is selected using the same assay, then the 20 isolated compounds are singularly 
prepared and tested, arriving to the identification of the most active component.  
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Table 5: Properties of “Amino acidic Building blocks” used in 
the library design  
 
 
Selected 
Amino Acid 
1-
Lette
r 
 
Side 
chain 
Side chain properties 
 
Glutamine Q -CH2CH2CONH2 polar neutral Amide 
Serine S -CH2OH polar neutral Hydrophobic 
Arginine R -(CH2)3NHC(NH)NH2 polar Basic 
(strongly) 
 
Alanine A -CH3 Non 
polar 
neutral Hydrophobic 
Tyrosine Y -CH2-C6H4OH polar neutral Aromatic 
Proline P -CH2CH2CH2 Non 
polar  
neutral Hydrophobic 
Methionine M -CH2CH2SCH3 Non 
polar 
neutral Hydrophobic 
Cysteine C -CH2SH Non 
polar 
neutral  
Phenylalanine F -CH2C6H5 Non 
polar 
neutral  Aromatic 
Leucine L -CH2CH(CH3)2 Non 
polar  
Neutral Aliphatic 
Histidine H -CH2-C3H3N2 polar Basic 
(weakly) 
Aromatic 
Aspartic acid D -CH2COOH polar acidic  
 
 
The Fmoc group and the spacer were subsequently removed and replaced by 
an acetyl group; therefore all active peptides had a general formula as follows: 
 
 
 
Ac-X1-X2-X3-X4-CONH2 
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2.7 Binding and competitive Enzyme-Linked 
Immunosorbent Assay (ELISA)  
 
2.7.1 Biotinylation of Gadd45β 
 
Fractions of Gadd45β (1 mg/ml) were biotinylated using an EZ Link NHS-LC-
biotin kit (Pierce), according to the manufacturer's instructions, but with slight 
modifications. One volume of 2 mg/mL NHS-LC-biotin was added to 20 
volumes of protein and incubated on ice for 1 h; the reaction was then 
stopped by addition of one volume of 50 mM glycine. Biotinylated samples 
were dialyzed against buffer A (25 mM Tris, 150 mM NaCl 1 mM EDTA, 1 mM 
DTT, pH 7.5) to remove excess glycine and free biotin, and stored at −80 °C. 
The incorporation of one biotin moieties per molecule of protein was recorded 
by LC-MS analysis. 
 
 
2.7.2 Gadd45β -MKK7 association and competition 
ELISA assays 
 
Association between Gadd45β and MKK7 was investigated by ELISA assays 
by coating the GST-fused full length kinase for 16 h at 4 °C, at a concentration 
of 42 nM in buffer A (25mM Tris pH 7.5, 150mM NaCl, 1mM DTT and 1mM 
EDTA) into a 96-well microtiter plate (Coating). Some wells were filled with 
buffer alone and were used as blanks. After incubation for 16 h at 4 °C, the 
solutions were removed and the wells filled with 350 µL of a 1% (w/v) solution 
of NFDM (Non Fat Dry Milk) in PBS (Blocking). The plate was incubated for 1 
h at 37 °C in the dark. After washing with buffer T -PBS (PBS with 0.004% 
(v/v) Tween), the wells were filled with 100 µL of biotinylated Gadd45β at 
concentrations ranging between 8.4 nM to 168 nM (Binding). Each data point 
was performed in triplicate. Following incubation for 1 h in the dark at 37 °C 
the solutions were removed and the wells again washed with T-PBS. Then 
100 µL of 1:1000 horseradish peroxidase-conjugated streptavidin dissolved in 
buffer was added to each well and the plate incubated for 1 h at 37 °C in the 
dark (Binding Signal amplification). After removal of the enzyme solution and 
washing, 100 µL of the chromogenic substrate o-phenylendiamine (0.4 mg/ 
mL in 50 mM sodium phosphate-citrate buffer, containing 0.4 mg/mL of urea 
in hydrogen peroxide) was added and the colour was allowed to develop in 
the dark for 5 min. The reaction was stopped by adding 50 µL of 2.5M H2SO4 
(Detection). The absorbance at 490 nm was measured in all wells and the 
values were averaged after subtracting the corresponding blanks. Bound 
protein was then detected as described above. KD values were estimated as 
the concentration of protein able to give half of the saturation signal. Binding 
competition assays were performed by coating GST-MKK7 at 42 nM as 
described, a concentration of biotinylated Gadd45β of 21 nM (pre-saturation 
conditions 1:0.5 mol/mol ratio) and using 12 pools of peptides as competitors 
at a 2:1 competitor/soluble protein ratio (total concentration of competitors 42 
nM assuming an average molecular weight of 1000 Da for each peptide). 
Competition results are reported as (B/B0)x100, where B means the average 
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OD from the triplicate data point for a given analyte and B0 is the average OD 
determinated without competitors (Analysis). Data were all fitted using the 
GraphPad Software, GraphPad, San Diego, California, USA. 
 
 
 
2.7.2 Dose dependent competition assay 
 
Dose-dependent competition assays were carried out to monitor the efficiency 
of antagonist selected from combinatorial libraries. For this purpose, 100 µl of 
42 nM GST-fused full-length kinase in buffer A was coated on multi-well 
plates overnight at 4 °C. After blocking with NFDM for 1 h and washing with 
TPBS, increasing concentrations (from 0.168 nM to 0.105 µM) of lead 
compound 1 and 2  and one negative control  were pre-incubated with 21nM 
biotinylated Gadd45β for 30 min before addition to each well. The subsequent 
steps of the ELISA assays were carried out as described before. 
 
 
2.7.3 Gadd45β self-association and competition ELISA 
assays 
 
An ELISA-like assay was used to monitor Gadd45β dimerization. For this 
purpose, Gadd45β at concentration of 0.52 µM in buffer A was dispensed into 
a 96-well microtiter plate. The steps of coating, washing, blocking, signal 
amplification and detection were performed as previously described. Instead 
the step of binding was carried out filling the wells with 100 µL of biotinylated 
Gadd45β at concentrations ranging between 16 µM and 2.1 µM.  
A binding curve was obtained and the concentration of  biotinylated Gadd45β 
resulting in a 50% of maximum binding was taken as an estimate of the 
dissociation constant of self-association. 
For the competition experiments, 100 µL aliquots of 0.52 µM His6-Gadd45β 
were coated on the wells of a microtiter plate and 0.26 µM biotinylated His6- 
Gadd45β (molar ratio 1:0.5) was used throughout (presaturation condition). 
Peptides (0.52 µM) from trypsin digestion or the synthetic peptides 
corresponding to the protein helices, were used as competitors at a molar 
ratio of 1:1 to coated unbiotinylated protein. Competitors were pre-incubated 
with 0.26 µM biotinylated Gadd45β for 30 min at 4 °C before addition to each 
well. Peptides derived from the trypsin digestion were used at a nominal 
concentration of 0.52 µM, calculated assuming a 100% trypsin cleavage and a 
100% recovery from the HPLC fractionation. GST-MKK7, Gadd45β eH1, eH4, 
and eH5, and the synthetic peptides MKK7(G132-N156) and Gadd45β(A60-
D86), were always used at a concentration of 0.52 µM. ELISA assays were 
carried out at least in duplicate. Competition results are reported as (B/B0) X 
100, where B is the average absorbance from the triplicate data points for a 
given analyte and B0 is the average absorbance determined without 
competitor. 
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2.8 Tissue culture and transfection assays 
 
Human epithelial cells (HEK293) were cultured using Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum, 100 
units/ml penicillin, 100 mg/ml streptomycin, and 1% glutamine. HEK293 cells 
(2.2x10 6) were seeded in 10 cm dishes the day before the transfection in 
DMEM. They were transfected with 1 µg of pEGFP and 25 µg of 
pcDNAFlagMKK7 or 25 µg of pcDNAHAGadd45β, using Ca3(PO4)2 
precipitation technique. Forty-eight hours after the initiation of transfection, the 
efficiency was determined using a FACScalibur (Becton Dickinson) 
instrument, with the help of the Cellquest software to detect the variation of 
GFP fluorescence intensity between untransfected and trasfected cells. 
Subsequent data analyses were obtained using the Flow Jo program.  
The co-transfection of two proteins was carried out as previously described, 
using ever 1 µg of pEGFP to monitor the efficiency of transfection and  
different DNA ratio pcDNAFlagMKK7:pcDNAHAGadd45β.  
 
 
2.9 Cell lysis  and western blot analysis 
 
The transfected cells were washed once with PBS, lysed for 30 min at 4°C in 
buffer B (20 mM HEPES, 350 mM NaCl 20% glycerol 1 mM MgCl2, 0.2 mM 
EGTA,1 mM DTT, 1 mM Na3VO4 and 50 mM NaF), supplemented with 1 mM 
phenylmethylsulfonylfluoride, 10 µM of chymostatin, 2 µg/ml of aprotinin, and 
2 µg/ml of leupeptin with occasional gentle shaking. The lysed cells were 
collected and centrifuged at 20000xg for 20 min, and cleared lysates were 
used for further analysis. The protein concentration in the supernatants was 
determined by the Bradford method. Lysates were fractionated by 15% SDS– 
PAGE gels under reducing conditions and then electrotransferred to 
nitrocellulose. The nitrocellulose filters were blocked for 1h at room 
temperature and then incubated with opportune primary antibody  for 90 min. 
After three washes with TBS/0.1%Tween 20, the blots were incubated for 1h 
with proper horseradish peroxidase-conjugated (HRP) secondary antibody, 
washed extensively and developed by enhanced chemiluminescence (ECL, 
Amersham, Arlington Heights, IL), according to the manufacturer’s 
instructions. 
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Table 6: Antibody  
 
Detected samples Primary Antibody Secondary Antibody 
Gadd45β αGadd45β  1: 100 α Mouse 1: 2000 
Mkk7  MEK-7 (T-19) 1: 2000 
 
α goat 1:2000 
HAGadd45β/HA MKK7  HA-probe (Y-11)  1: 200 
 
αRabbit 1:1500 
Flag Gadd45β/Flag MKK7 αFlag 1: 2000 
 
α Mouse 1:5000 
Phospho-SAPK/JNK  αPhospho-SAPK/JNK 
(Thr183/Tyr185) 
1: 200 
α Rabbit 1:1500 
 
 
 
 
2.10 Activation of MKK7 immunoprecipitation  and  
kinase assays 
 
Transient transfections of pcDNAFlagMKK7 were performed with the 
Ca3(PO4)2 precipitation technique. After 36h, the cells were serum-starved 
overnight and treated with TNFα (2000 u/mL) and Pma/ionomycin (100 ng/ml 
– 1µM), respectively, for 10 min and 30 min at 37°C . Cell extracts were 
prepared as previously described. In pull-down experiments, 50 µg of Flag-
MKK7 cell lysate was incubated with 20 µl of anti-FLAG@ M2 Affinity Gel 
(SIGMA), for 1h at 4oC with rotation. The immunoprecipitates were washed 
three times with lysis buffer without inhibitors and subjected to SDS–PAGE. 
After immunoprecipitation, the beads were washed 3 times in lysis buffer, and 
twice in Kinase Buffer (10 mM HEPES, 5 mM MgCl2, 1 mM MnCl2,12.5 mM β-
glycerophosphate,  2 mM DTT, 4 mM NaF and 0.1 mM Na3VO4). The MAPK 
activity was measured at 30°C for 20 min in 20 µl o f kinase buffer containing 2 
µM of recombinant GST–JNK and 0.2 mM ATP or 5 µCi of [γ-32P]ATP). The 
reactions were terminated by addition of Laemmli sample buffer. Proteins 
were resolved by 10% SDS–PAGE and identified by Western Blotting or 
autoradiography. The incorporation of [32P] phosphate into the GST fusion 
protein was quantitated by Phosphor Imager analysis. 
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2.11 Binding and Competition Assay by combined 
Immunoprecipitation, Kinase Assay and Western 
Blotting 
 
To monitor MKK7 inactivation by Gadd45β and the ability of peptides 
antagonists to revert this effect by disrupting the Gadd45β-MKK7 interaction,  
cell lysate immunoprecipitated Flag-MKK7 (50 µg, obtained as previously 
described, was pre-incubated for 10 min in absence and in presence of 
synthetic peptides (at different concentration from 1 nM to 1 pM). The 
mixtures were next incubated with 5 µM GST-Gadd45β and 2 µM GST-JNK 
(purified from bacterial lysates) and the incorporation of [32P] phosphate 
groups into GST-JNK was monitored Phosphor Imager analysis. 
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3.1. Gadd45β cloning, expression and purification 
 
The recombinant construct pGEX6P-GADD45β allowed the expression of the 
protein as a GST-fusion product containing a highly specific cleavage site for 
PreScission Protease upstream of the Gadd45β protein. The applied 
overexpression system was quite efficient, producing more than 6 mg of 
highly purified protein from 1 L of induced culture under optimized conditions, 
as described in materials and methods. The isolated protein was 98% pure 
after a purification step on anionic exchange column and was characterized 
by SDS–PAGE and LC–MS to assess purity and MW. The MW was in very 
good agreement with that calculated 18096.6±1.0/18096 (inclusive of the 
GPLGS linker left from proteolytic cleavage). The investigation of Gadd45β 
cysteines redox state was carried out through extensively alkylation of   
cysteine thiols with 4-VP and subsequent analysis by LC-MS to determine the 
exact MW. The Gadd45β mass spectrum after 4-VP alkylation shows that the 
protein undergoes an increase of molecular weight of 630 Da, corresponding 
to the incorporation of six 4VP-moieties, confirming the absence of any 
disulfide bridge between the six cysteines. SDS analyses of Gadd45β purified 
fractions and LC-MS characterization before and after alkylation are shown in 
the following panel A.  
Human Gadd45β was expressed also as a recombinant protein with an N-
terminal His6 tag using the vector pET28aGADD45β.  
The expression conditions were optimized obtaining more than 7 mg of pure 
protein from 1 L of bacterial culture. The protein after two purification steps by 
affinity and anionic change chromatography was about 95% pure. 
Furthermore, this protein was efficiently derivatized with biotin as described in 
the Methods section. Protein derivatization was assessed by mass 
spectrometry showing that about 90% of the protein harboured one biotin 
molecule, while the remaining appeared underivatized. The experimental MW 
of 19196.5 amu as determined by LC-MS was consistent with that expected 
on the basis of the sequence and one biotin molecule (19196.52 amu). His6-
Gadd45β was used in ELISA assays to identify regions involved in auto-
association. SDS-PAGE analysis of the recombinant protein and the 
successive LC-MS characterization are reported in the panel B. 
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Panel A: Expression and LC/MS characterization of 
hGadd45β 
 
Gadd45β was cloned in the pGex6P-1 expression vector allowing the 
expression of the protein as GST-fusion product containing a highly specific 
cleavage site for PreScission Protease upstream of Gadd protein. The 
purification was achieved on a Glutatione  Sepharose 4B and on–column 
cleavage was carried out at 6 °C for 4h (Fig. 1A).  The final purification step 
was realized on an anionic exchange column (Fig. 2A). In order to investigate 
the presence of reduced cysteines, was carried out an extensive alkylation of 
the protein which was subsequently analyzed by LC-MS (Fig 3A and 4A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1A: 15% SDS-PAGE analysis of the recombinant protein; Lane 1: Perfect 
Protein Marker,15-150 kDa; Lane 2: clarified bacterial lysate of BL21(DE3)TrxB 
transfected with pGEX6P-1/GADD45β vector; Lane 3: flow through; Lane 4-5-6:  
eluates containing the cleaved  protein. 
 
 
 
Fig. 2A: 15% SDS-PAGE of purified fractions; Lane 1: Perfect Protein Marker,15-150 
kDa; Lane 2: pool of  fractions purified from Glutathione Sepharose matrix; Lane 3: 
flow through;  Lane 4-9: eluates at 340 mM NaCl containing Gadd45β with a purity of 
98%. 
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Fig. 3A: Deconvoluted mass spectrum of underivatized Gadd45β showing a 
molecular weight of 18096.6 ± 0.5 Da, in very good agreement with the theorical 
value of 18098.3 Da, assuming that all cysteines were in the reduced state. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4A: Deconvoluted mass spectrum of Gadd45β after 4-VP alkylation. The 
spectrum shows that the protein undergoes an increase of molecular weight of 630 
Da, corresponding to the incorporation of six 4VP-moieties, confirming  the reduced 
state of all the six cysteines. 
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PANEL B: Expression and derivatization of 
His6Gadd45β 
Human Gadd45β was expressed as a recombinant protein with an N-terminal 
His6 using the vector pET28GADD45β. Purification was achieved on His Trap 
Hp, 1mL prepacked with precharged Ni-Sepharose. The bound protein was 
eluted using an imidazole gradient from 10 to 500 mM (Fig. 1B).  The protein 
was efficiently derivatized with biotin (Fig. 2B) and used in Elisa assays  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1B: 15% SDS-PAGE analysis of the recombinant protein; Lane 1: Perfect 
Protein Marker,15-150 kDa; Lane 2: total bacterial lysate of BL21(DE3) transfected 
with pET28-GADD45β vector; Lane 3: clarified bacterial lysate of BL21(DE3) 
transfected with pET28-GADD45β vector;  Lane 4: flow through; Lane 5-8:  Eluates 
containing the purified protein. 
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Fig. 2B: Assessment by mass spectrometry of Gadd45β derivatized with biotin. 
About 90% of the protein harboured one biotin molecule, while the remaining 
appeared underivatized. 
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3.2. MKK7 cloning, expression and purification 
 
MKK7 was produced in bacteria as a soluble GST-MKK7 fusion product. 
About 7 mg/L of the fusion protein were obtained in typical fermentations. The 
protein was initially purified by standard GSTrap and the GST was removed 
by on-column PreScission protease cleavage. The material recovered was 
further purified by gel filtration chromatography, obtaining a product more than 
95% pure. MKK7 characterization by SDS-PAGE, circular dichroism and 
exclusion chromatography are reported in panel C. The folding of MKK7 was 
assessed by CD analysis observing, as expected on the basis of its high 
similarity with other kinases a spectrum with a mixed α-β content. Gel filtration 
analysis confirmed the oligomeric state of the protein. Indeed, MKK7 eluted 
on the gel filtration column as a dimer (apparent MW of about 90 kDa), in 
agreement with previous reports on other similar kinases (75) Importantly, 
also the fusion protein GST-MKK7, used in several assays in this study, 
eluted from the gel filtration column as a dimer. 
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Panel C : Expression and characterization of hMKK7 
 
Human MKK7 kinase was expressed as a recombinant protein with an N-
terminal GST using the vector pGex6p1-MKK7 (Fig 1C). The fusion protein 
has been removed by PreScission protease cleavage (Fig 2C). The 
preliminary structural characterization showed that the recombinant human 
MKK7 is properly folded exhibiting a prevailing alpha-helical conformation 
(Fig. 3C). The protein appears to be dimeric upon gel filtration analysis (Fig. 
4C). 
 
   
 
 
 
 
 
 
 
                                         
 
 
 
 
 
Fig. 1C: 12% SDS-PAGE analysis of purified GST-MKK7. Lane 1: protein marker 15-
150KDa; Lane 2: pGex6P1-MKK7 transformed into BL21 (DE3) trxB but not induced; 
Lane 3: total bacterial lysate after induction; Lane 4: clarified bacterial lysate; Lane 5: 
eluate containing the protein  GST-MKK7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2C: 12% SDS-PAGE analysis of purified cleaved MKK7. Lane 1: fraction 
containing the cleaved protein: Lane 2: protein marker 15-150KDa. 
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Fig. 3C: CD spectrum in the near UV of MKK7 showing that the protein adopts a 
prevailingly alpha helical conformation, as expected on the basis of a very high 
sequence conservation with other kinases whose structures have been solved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4C: Calibration curve used to determine the apparent MW of recombinant MKK7 
protein by gel filtration analysis. Ovalbumin, 44 kDa; BSA, 66 kDa;Transferrin, 81 
kDa; Catalase, 206 kDa; Ferritin, 460 kDa. The protein appears to be dimeric. All 
determinations were carried out under the same conditions and repeated at least 
twice. 
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3.3 Investigation of Gadd45β oligomerization by size 
exclusion chromatography analysis 
 
Since previous studies reported on the capacity of Gadd45 proteins to 
oligomerize (64), this issue was investigated by carrying out a gel filtration 
analysis in the presence and/or absence of DTT and by native electrophoresis 
experiments. Gel filtration analysis of protein aliquots at the concentration of 
5.0 µM, showed that, in absence of DTT, two peaks were eluted at column 
volumes corresponding to a dimeric and tetrameric protein, that is 36 kDa and 
72 kDa, respectively (panel D, Fig. 1D and 3D). Conversely, under reducing 
conditions, the tetramer peak disappeared (Fig. 2D), indicating that it was held 
together by disulfide bridges, whereas the dimer was associated through 
strong non-covalent interactions. The presence of protein dimer or oligomer 
was also investigated by native gels, observing in this case the dimer and the 
monomer (Fig. 4D). According to these data, Gadd45β seemingly exists in 
solution prevalently as a dimeric protein, in partial equilibrium – under certain 
conditions (the non-denaturing gel) – with the monomer. Indeed, no higher 
order oligomers have been detected by either techniques. 
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Panel D: The assessment of Gadd45β oligomeric state 
by hydrodynamic methods 
 
 
 
 
 
 
 
 
 
Fig. 1D: Gel filtration analysis on a Superdex 75 10/30 of Gadd45β protein under 
non reducing conditions. Two peaks at elution volumes compatible with dimeric and 
tetrameric forms are detected. 
 
 
 
 
 
 
 
 
 
Fig. 2D: Analisis by size exclusion chromatography carried out after addition of 1 mM 
DTT in the running buffer. The peak at lower elution volumes disappeared, 
suggesting that it is due to covalent disulfide bridges. 
 
 
 
 
 47 
 
 
 
 
 
 
Fig. 3D: Calibration graph of partition coefficient (Kav) versus molecular mass of 
several protein standards: Cytochrome C, 12.4 kDa; RNase A, 14.7 kDa; 
Chymotrypsinogen, 25.0 kDa; Carbonic anhydrase, 29.0 kDa; Ovalbumin, 44.0 kDa; 
BSA, 66.0 kDa. All determinations have been performed at least twice. 
 
 
 
 
 
 
Fig. 4D: Non-denaturing polyacrylamide gel analysis of Gadd45β.Lane 1: Sea Blue 
marker (250-22 KDa); Lane 2: Gadd45β at a concentration of 1.8 mg/mL (100 µM). 
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3.4 Spectroscopic characterization of Gadd45 β 
 
The far-UV CD spectrum of Gadd45β (11x10-6 M) in aqueous solution showed 
two negative bands at 209 and 222 nm and a positive band at 195 nm 
indicative of a high content of α-helical conformations (See panel E, Fig. 1), as 
previously reported (61). Importantly, also the His6-Gadd45β, utilized in 
different assays exhibited a very similar CD spectrum (not shown). The 
occurrence of oligomers was also investigated by this technique by 
comparative analysis of protein solutions at different concentrations. No 
differences were detectable between CD curves recorded on protein solutions 
at concentrations ranging between 5.5 x 10-5 M and 5.5 x 10-6 M  (data not 
shown) suggesting that dilution, at least in the range of the explored 
concentrations, did not affect the protein global folding nor the quaternary 
structure. Therefore, no indications could be obtained on the actual monomer-
dimer status of the protein by this experiment. A CD analysis of the 
dependence on denaturant concentration was also performed to further 
assess the protein structure stability or the capacity to eventually dissociate 
into monomers. Chemical denaturation data (Fig. 2E and 3E) showed that 
Gadd45β unfolds cooperatively at about 2.0 M GdnHCl and 3.0 M urea. This 
may indicate that electrostatic interactions, which are more efficiently 
weakened by GdnHCl than by urea (74), play an important role in stabilization 
of Gadd45β.  
Upon denaturant removal, the protein secondary structure was recovered 
(Fig. 1E), suggesting that denaturation, as well as the eventual dimer 
dissociation (assuming it occurs at high denaturant concentration), is a 
reversible event. Also thermal denaturation experiments were carried out to 
confirm these observations; a single transition was observed at about 46.5 °C, 
but, most importantly, after slow cooling back to 20 °C, the protein could not 
recover the original structure because of disulfide cross-linking. The melting 
temperature is quite low in comparison to those of other globular proteins 
indicating that Gadd45β is not a thermodynamically stable protein, according 
to the predicted structure that exhibits large and flexible loops (67) 
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Panel E: Circular dichroism characterization of the 
recombinant Gadd45β 
 
CD spectra of the recombinant protein before and after denaturation with 
guanidinium and urea are reported in Fig. 1E. The protein appeared to 
properly refold after the chemical treatment. Spectra at 7.5 M urea and 
guanidinium (dotted lines) are also reported. The curves of chemical 
denaturation are representative of at least two independent experiments. CD 
curves were obtained by averaging at least three consecutive acquisitions. In 
Fig. 2E the chemical denaturation by GdnHCl is reported. The protein unfolds 
in a cooperative way at guanidinium concentrations higher than about 2.5 M 
(See also Fig. 1E). In Fig 3E the chemical denaturation by urea is also 
reported. In  this case the protein unfolds cooperatively at concentrations 
higher than about 4.0 M. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1E 
Fig. 2E Fig. 3E 
Fig. 1E 
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3.5 Identification of regions of Gadd45β involved in 
auto-association 
 
3.5.1 The rationale of the strategy 
 
Identifying interaction sites between proteins requires powerful techniques 
and methodologies such X-Ray diffraction and high field NMR, for which large 
amounts of highly pure proteins are needed. Secondary structure motifs and 
small protein domains can be used as models isolated from the protein 
context and investigated by several techniques to gain structural insights on 
the protein global structure and to modulate interactions with external 
partners. While awful progresses have been made in this field by using de 
novo designed synthetic peptides, the idea of using protein fragments 
obtained by chemical or enzymatic methods  have  been only rarely pursued. 
Chemical methods, though equally selective in cleaving proteins on selected 
residues, are always carried out under harsh conditions that invariably lead to 
protein unfolding. On the other hand, enzymatic proteolysis of folded proteins 
under mild conditions, acting preferentially on exposed and less structured 
sites, can help to isolate shorter polypeptides with partially preserved 
secondary and tertiary structures. These structurally selected protein blocks 
could work as “reminders” of the original structure and, as such, can be 
usefully utilized as probes for structural studies and as tools for the 
identification of protein-protein interaction contacts. We have optimized this 
process and developed a novel method to rapidly and cheaply obtain useful 
insights on protein-protein interaction sites that can be successively utilized to 
support or refine available structural data by classical techniques. The 
methods is based on the use of ELISA assays, whereby protein binding is 
firstly optimized in order to determine affinity constants and the pre-saturation 
concentrations needed to carry out binding competition assays. Proteins are 
subsequently degraded by trypsin, and the resulting peptide fragments are 
utilized as competitors to select those able to disrupt the binding. 
Following this approach regions of Gadd45β implicated in self-association 
were identified and characterized.  
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3.5.2 Characterization of regions of Gadd45β involved 
in auto-association 
 
Firstly an ELISA assay to monitor Gadd45β self-association was carried out 
by coating the His6-protein on the surface of microtiter wells. Protein 
association was followed by adding increasing amounts of biotinylated His6-
Gadd45β and detecting the bound protein by using HRP-STRV. As shown in 
Panel F (Fig. 1F),  the protein efficiently associated in a dose-dependent way, 
reaching signal saturation at a nearly 1:1 (mol/mol) ratio, as expected by a 
dimeric complex. The concentration of His6-Gadd45β resulting in a 50% of 
maximum binding was around 100 nM and it was taken as an estimation of 
the dissociation constant of self-association. 
Subsequently, an extensive digestion of a protein aliquot was carried out with 
trypsin which resulted in complete digestion and formation of fragments of 
suitable length to ensure a complete coverage of the protein primary structure 
(See panel F; Table 1). Upon RP-HPLC fractionation (13 fractions), Gadd45β 
peptides, identified by MW and MS/MS sequencing, were essentially 
distributed along 7 main fractions, since fractions 1-5 contained no material 
and fraction 11 contained only very small amounts (less than 4%) of fragment 
L46-R91. All identified trypsin fragments are reported in Table 1 along with a 
correspondence with the predicted Gadd45β secondary structure (67). 
Fractions 6, 7, 8 ,9, 10, 12 and 13 contained relevant amounts of the protein 
fragments. Notably, fraction 6 only contained the C-terminal G147-R160 
peptide (unstructured); fraction 7 contained, in a 1:1 ratio, fragments L36-K45 
(Part of β1 and part of α2) and L98-R115 (Part of α4; most of loop 2); fraction 
8 contained (in a 85:15 ratio), a major fraction of fragments S132-R146 (87%, 
the central region of α5, hereafter H5 short) and the peptide D116-K131 (β4); 
fraction 9 contained, in a 75:25 ratio, the N-terminal polyhistidine tag and a 
minor fraction of the peptide S132-R146 (α5); fraction 10 contained only the 
fragment M16-R32 (92%, the remaining being distributed along the 
contiguous fractions), corresponding to most of helix 1; fraction 12 and 13 
contained the fragment L46-R91, corresponding to part of α2, β2, loop1, α3, 
and part of β3. Finally, to identify the Gadd45β regions involved in protein 
dimerization, binding competition assays were carried out using peptide 
fragments. The assays were performed using an invariable 1:0.5 (mol/mol) 
ratio of coated/soluble His6-Gadd45β and a 2:1 (mol/mol) ratio of peptide 
competitor/soluble protein. The results are summarized in the panel F, Fig. 1F 
where a plot of representative data is reported. Gadd45β trypsin fractions 
from 1 to 5 and fraction 11 were not utilized. Fractions 6, 7, 12 and 13 which 
contained consistent amounts of protein fragments (see Table 1), but they 
were essentially ineffective. In contrast, fractions 8 to 10 interfered with the 
association. In particular, fraction 8 exhibited a nearly 30% binding reduction, 
fraction 10, which virtually contained only fragment M16-R32 (see Table 1) 
corresponding to most residues of helix 1, decreased protein association to 
about 50%, whereas fraction 9, containing most residues of the tag and a 
minor part of fragment S132-R146, disrupted Gadd45β self-association by 
25%. Interestingly, the synthetic peptides Gadd45β (A60-D86) and MKK7 
(G132-N156), identified as forming the binding interface between Gadd45β 
and MKK7 (47;67) appeared totally ineffective in this assay. To further refine 
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the ELISA data, those fragments unable to disrupt Gadd45β-Gadd45β 
interaction were not considered; furthermore, on examination of the predicted 
Gadd45β 3D model (panel F, Fig. 3F), it was decided to not further investigate 
the fragment D116-K131, present in fraction 8 at 15%, since it corresponds to 
the fourth β-strand which should be buried within the protein core and 
therefore virtually inaccessible to external interactions (panel F, Fig. 3F).  The 
regions M16-R32 and S132-R146 corresponding to the regions within the 
putative H1 and H5, respectively have been successively investigate. 
Examining the protein model, (panel F, Fig. 3F) the peptides were opportunely 
designed by adding N- and C-terminal amino acids in order to complete the 
helices, hence the corresponding synthetic peptides, A12-R35 (hereafter 
extended Helix 1, eH1) and A129-N148 (hereafter extended Helix 5, eH5) 
were prepared by chemical synthesis and purified to homogeneity by RP-
HPLC. The peptide R91-E104, corresponding to the extended predicted eH4, 
was also similarly prepared and utilized as a negative control. These peptides 
were then tested in the Gadd45β-Gadd45β competition assay, using the 
same protein-protein and protein-competitors ratios as described previously. 
As shown in the same panel F, Fig. 2F, eH1 and eH5 blocked the Gadd45β 
self association by 82% and 78%, respectively, supporting the hypothesis that 
these regions are strongly involved in the interaction. On the contrary, peptide 
R91-E104 (eH4), lying in the model in the close proximity of H1, as well as 
peptides Gadd45β(A60-D86) and MKK7(G132-N156) and the full length 
kinase did not interfere with the protein homodimerization. A dose-dependent 
competition assay carried out with eH1, eH5, the short H5, eH4 and full length 
MKK7, further confirmed the properties of H1 and H5 and the inefficacy of H4 
to abrogate dimerization (Panel F, Fig. 4F). As expected, the full length kinase 
(fused to GST) was unable to block the Gadd45β self-association even at 
higher concentrations. Remarkably, the IC50 for these competitors were 100 
nM for H1, 180 nM for the extended Helix 5 and only 600 nM for the short H5, 
indicating that the full H5 was more than 3 times efficient in disrupting the 
protein self-association. These results might account for the relatively weak 
inhibition exhibited by fractions 8 (30%) and 9 (25%) which only contained the 
shorter variant of the H5.  The combination of the method of limited enzymatic 
proteolysis and LC-MS characterization permitted to identify the regions of 
Gadd45β involved in the self association corresponding to the predicted H1 
and H5 of protein The results have been validated by model building which 
shows how the dimerizzation region can form a four-helix bundle (see Fig.5F). 
The contiguous disposition of H1 and H5 in one monomer creates a large 
hydrophilic surface interacting in an anti-parallel fashion with the 
corresponding helix of the other monomer. 
In particular the residues Gln13 Thr14 and Glu21 on H1 and Glu140, Tyr137, 
Glu133 and His 129 on H5 are involved in a network of intra-molecular polar 
interaction which stabilizes the structure of the complex. 
The 3D model still supports the view that Gadd45β is unable to form higher 
order complexes. In fact the absence of an alternative and independent site 
involved in the auto association does not permit an oligomerization.  
The predicted helix H4, being parallel to H1, virtually extends the interaction 
surface towards the protein Loop 2 but does not contribute to protein self-
association. On the contrary it is reportedly involved in the binding with MKK7 
(47;61).  
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Panel F:  Detection of Gadd45β regions implicated in 
self-association 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1F: Dose-dependent binding of biotinylated Gadd45β to the plate-adsorbed 
protein: Gadd45β self associates with an estimated KD of about 100 nM, assumed 
as the concentration of Gadd45β resulting in 50% maximum binding. Notably, the 
signal reaches saturation at a 1:1 protein ratio, suggesting the formation of dimers 
only. 
 
 
Fraction Gadd45β 
tryptic 
peptides 
Relative 
distribution of 
fragments 
within 
fractions (%) 
Relative 
composition 
of the fraction 
(%) 
Predicted 
secondary 
structure* 
 
6 G147-R160 98 100 Unstructured 
7 L36-K45 
L98-R115 
98 
99 
50 
50 
Part of β1, part of 
α2  
Part of α4; most of 
loop 2 
8 S132-R146 
D116-K131 
87 
99 
85 
15 
α5 
β4 
9 -13-15  
S132-R146 
100 
5 
75 
25 
Tag 
α5  
10 M16-R32 92 95 α1 
12 L46-R91 10 100 Part α2, β2, loop1, 
α3, part β3 
13 L46-R91 87 100 Part α2, β2, loop1, 
α3, part β3 
 
 
Table 1: Tryptic Gadd45β peptidic fragments have been identified by LC-MS/MS 
analysis. Fragments less than 5% were not considered. Relative distributions of 
fragments in column 3 were calculated by comparing area integration of extracted ion 
peaks from a given fragment taken from the different fractions. The relative 
composition within each fraction was derived by comparing area integrations of 
extracted ion peaks of all the fraction components. *As reported in reference 1. 
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Fig. 2F:. Competition assay of the Gadd45β self-association by the trypsin-
generated protein fragments and by synthetic peptides designed to reproduce helices 
as predicted in the protein model (67). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3F: A ribbon representation of Gadd45β three-dimensional model, coloured by 
residue type according to the following scheme: hydrophobic residues, white; polar 
residues, yellow; acidic residues, red; basic residues, blue; histidine residues, cyan; 
tyrosine residues, in pink (67). 
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Fig. 4F: Dose-dependent inhibition of Gadd45β self-association by GST-MKK7 full 
length, eHelix 4 (residues 91-104), eHelix 5 (residues 129-148), eHelix 1 (residues 
12-35) and the Helix 5 short (residues 132-146). While the kinase and the eHelix 4 
are not able to block the Gadd45β self-association, peptides corresponding to eHelix 
1 and eHelix 5, potently reduce the association. The Helix 5 short, derived by trypsin 
cleavage, is less effective than the entire eHelix 5. Data are representative of at least 
3 independent experiments. 
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Fig. 5F: Two orthogonal views of Gadd45β homo-dimer three-dimensional model in 
ribbon representation, rotated around the horizontal axis of the figure. One monomer 
is colored in pink, the other in pale green. Helices H1 and H5 of each monomer are 
colored in magenta and dark green, respectively. Residues lying on these helices are 
shown in stick representation and colored according to the following scheme: 
hydrophobic residues in white, acidic residues in red, basic residues in blue, histidine 
in cyan and tyrosine in magenta. 
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3.5.4 Gadd45β eHelices characterization by CD 
 
The synthetic peptides reproducing eH1, eH5, the short H5 and the eH4 were 
analyzed by CD. The analyses were carried out in both phosphate buffer and 
in the presence of 20% TFE to measure the relative propensity of peptides to 
adopt α-helical conformations. As reported in the Panel G, whereas eHelices 
1, 4 and 5 adopted a partially folded structure in buffer and readily folded into 
α-helices upon TFE addition, the short H5 remained in the unfolded state 
even after addition of the structuring solvent, suggesting an intrinsic incapacity 
to form organized structures. Thus, increasing the length at the N- and C-
termini of the putative H5 provided a 5-fold increase in potency that can be 
partially ascribed to the lack of any structure of this peptide. 
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Panel G: Spectroscopic characterization of Gadd45β 
helices 
 
CD spectra of synthetic peptides eHelix 1, eHelix 4, eHelix 5, Helix 5 short in 
neutral buffers and in the presence of 20% TFE are reported in Fig. 1G, 2G, 
3G and 4G, respectively. As shown, the complete predicted helices have a 
good propensity to adopt an α-helical conformation, whereas the short Helix 5 
persists in a random conformation even after addition of the structuring agent. 
This different property is likely contributing to the reduced peptide capacity to 
disrupt the MKK7-Gadd45β interaction. CD curves have been obtained by 
averaging at least three consecutive acquisitions. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1G Fig. 2G 
Fig. 3G Fig. 4G 
 59 
 
3.5.5 Gadd45β forms a homodimeric complex that 
binds tightly to MKK7 
 
To extend the knowledge of the interaction between the two monomers, an 
assay to monitor the binding between MKK7 and Gadd45β was carried out. 
Indeed this interaction has been thoroughly investigated in previous works by 
pull-down assays utilizing several point-mutated variants of both proteins (67). 
As shown in t Panel H (Fig. 1H), the association between the two purified 
proteins was very strong: a rough estimation of the KD, deduced by the 
Gadd45β concentration at half of the saturation signal, was about 13 nM. 
Noticeably, signal saturation was reached at an approximate 1:1 molar ratio, 
suggesting that one MKK7 molecule should be sufficient to bind to one 
molecule of Gadd45β. The competition experiment carried out using 42 nM 
MKK7, 21 nM Gadd45β and a twofold excess of competitors over the soluble 
protein, is reported in Fig. 2H. As shown, peptides corresponding to the 
putative extended Helices 1, 4 and 5, MKK7 (G132-N156) and Gadd45β 
(A60-D86) were utilized. Consistent with the notion that MKK7 proximity do 
not interfere with the Gadd45β dimerization, eH1 and eH5 do not affect the 
binding, whereas peptides Gadd45β (A60-D86) and MKK7 (G132-N156), 
believed to form part of the interface between the two proteins, completely 
abolish the interaction. The peptide R91-E104 corresponding to the putative 
eH4 and containing two key residues (M95/Q96) involved in kinase 
recognition (67), also proved ineffective to antagonize the Gadd45β-kinase 
binding, at the used concentration. Instead, soluble GST-MKK7, as expected, 
totally abolished the binding. Thus, these results corroborate the view that the 
Gadd45β-MKK7 interaction is essentially mediated by residues comprised 
within loop 1 and H3 (region A60-D86) (67), while other regions, such as H4, 
only partially contribute or may have only a structural role. 
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Panel H: Gadd45b dimerization does not affect MKK7 
binding and inhibition 
 
Gadd45β and MKK7 strongly interact (Fig. 1F) and their association is not 
influenced by Helix 1 or Helix 5. Instead Gadd45β [A60-D86] and MKK7 
[G132-N156], completely abolish the interaction. These data suggest that 
Gadd45β self association surface is distinct from that contacting the kinase 
MKK7 (Fig. 2F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Fig.  1H: Binding curve of the association between GST-MKK7 and Gadd45β. The 
estimated KD is 13 nM.  
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Fig. 2H: Binding competition of the MKK7- Gadd45β association by Gadd45β and 
MKK peptides. eHelix 1, eHelix 5, Helix 5 short and eHelix 4 cannot disrupt the 
binding, whereas Gadd45β [A60-D86] and MKK7 [G132-N156], corresponding to the 
interface between the two proteins, completely abolish the interaction. Also the GST-
fused full length kinase abolishes the interaction as expected. Data are 
representative of at least 3 independent experiments. 
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3.6 Biomolecular engineering by combinatorial 
chemistry and high-throughput screening 
 
3.6.1 Design of the combinatorial tetrapeptide library 
 
Designing and engineering small peptides that have specific structures or 
functions in biological pathways is a very challenging task. Indeed peptides 
have intrinsic flexible features and, despite the richness of side chain groups, 
they present an overall large structural similarity at the level of the backbone. 
Furthermore, as for the GADD45β-MKK7 complex only a theoretical model is 
available (61), we pursued an approach of screening random combinatorial 
libraries to select effective inhibitors of the interaction between the two 
proteins. Combinatorial libraries have gained widespread acceptance for the 
rapid preparation of enormous numbers of structurally related chemical 
compounds that are subsequently submitted to a screening assay to select 
active ingredients. In our case, a random tetrapeptides library in a simplified 
format (67) was designed and prepared to screen for effective peptide 
antagonists. To this purpose, a universal library was conceived with a 
minimum number of “non redundant” different amino acids (12 rather than 20) 
for the assembly of linear tetrapeptides. A tetrapeptide structure was chosen 
for it since it can mimic small molecules and can easily be re-converted in 
peptidomimetic compounds. Additionally they contain a limited number of 
rotatable bonds which restrains the amount conformational flexibility. The 
choice of the different amino acids was dictated by diversity in lipophilicity, 
MW, charge and polarity (See the Table 5 in Methods). Diverse monomers 
were chosen also to elude ambiguous sequencing by MS analysis. For 
example only Q and S were selected between the polar neutral amino acids, 
excluding their homologues N and T. 
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3.6.2 First generation simplified peptide libraries 
 
Peptide mixtures were obtained with a yield of about 70% (calculated on the 
basis of the final weight of crude products as compared to a theoretical MW 
obtained by averaging the molecular weight of residues). Peptide pools were 
characterized by LC-MS analyses, matching the experimental MW distribution 
with that expected by an equimolar mixture of the single peptides present in 
that mixture. Selected peptide mixtures were also characterized by pool 
aminoacid analysis, confirming the expected distribution of aminoacids (not 
shown). The success in preparing the peptide mixtures, was confirmed by the 
parallel synthesis of some test compounds having the same general structure 
and using the same synthetic procedures. Libraries were dissolved at a 
nominal concentration of 1 mM in pure DMSO (assuming an average MW of 
about 800 Da of all peptides) and dissolved in buffers in order to reach the 
concentrations required for screening.  
In the first screening assay, carried out by incubating the soluble biotin-
GADD45β with the different 12 sub-libraries (concentration 42 nM of total 
peptide concentration; the average concentration of the single peptides was 
about 24 pM), we observed that only the pool number 5 decreased the 
capacity of GADD45β-MKK7 binding by more than 98% (panel I, Fig 1). 
Therefore the sub-library Fmoc-βAla2-5-Y2-X3-X4 was synthesized as a set of 
12 new-sublibraries, each containing 144 different peptides. Also these 
libraries were characterized by LC-MS comparing the expected and the 
experimental MW distribution. Screening this second set of sub-libraries 
(concentration 42 nM of total peptide concentration; the average 
concentration of the single peptides was about 292 pM), we identified the pool 
12 (panel I, Fig 2I) as the best competitor of the GADD45β-MKK7 binding, 
providing a 95% signal reduction at the indicated concentration. On the basis 
of these data, the sub-library Fmoc-βAla2-5-12-Y3-X4 was re-prepared as a set 
of 12 sub-libraries each containing 12 different peptides. These peptide pools 
were easily characterized by LC-MS confirming the presence of all the 
expected molecules within the mixtures. By testing these sub-libraries 
(concentration 42 nM of total peptide concentration; the average 
concentration of the single peptides was about 3.5 nM), we observed that 
pools 3 and 12 resulted positive, showing almost complete blocking of the 
interaction (panel I, Fig 3I). Eventually, after further dose-dependent assays, 
sub-library 11 was chosen as the best working in that position. Finally, in the 
last screening cycle, 12 separated peptides with sequence Fmoc-βAla2-5-12-
11-Y4 were synthesized and screened. In this assay the single, purified 
peptides (fully characterized by LC-MS in terms of identity and purity), were all 
tested at a concentration of 42 nM; only the peptide Fmoc-βAla2-5-12-11-9, 
named lead peptide 1,  turned out to be able to block the interaction (panel I, 
Fig 4I) and was selected as the best molecule to be further studied and 
developed.  
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Panel I : Deconvolution of Combinatorial library 
 
The library deconvolution has been realized by Elisa competition assays. 
Competition results are reported as (B/B0) X 100, where B is the average 
absorbance from the triplicate data points for a given analyte and B0 is the 
average absorbance determined without competitor 
 
 
 
 
 
 
 
 
 
Fig. 1I : Screening of the library containing a theoretical total number of 124 = 20736 
different peptides, arranged in 12 different sub-pools. The sub-library 5 decreases 
the capacity of GADD45β-MKK7 binding with efficiency more than 98%. Therefore it 
was selected for re-synthesis.   
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Fig. 2I: Deconvolution of the sub-libraries Fmoc-(βAla)2-5-Y2-X3-X4-NH2. A 
theoretical total number of 1728 different peptides were arranged in 12 different 
pools. Only the sub pool 12 was chosen for re-synthesis. 
 
 
 
 
 
 
 
Fig. 3I: Screening of the library Fmoc-(βAla)2-5-12-Y3-X4-NH2. A theoretical total 
number of 144 different peptides were arranged in 12 different pools. Only the sub 
pool 11 was chosen for re-synthesis.  
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Fig. 4I:  Last step of iterative deconvolution. This fourth library was constituted by 
single peptides. Fmoc-(βAla)2-5-12-11-9-NH2, named Lead Pepide 1, was selected 
as the best library component of the interaction between GADD45β and MKK7. Its 
efficiency has been estimated to be more than 98% at a concentration of  42nM. 
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3.6.3 A new focused library of tetrapeptides 
 
To take into account for the peptide sequences not generated within the 
simplified library, a set of new peptides was designed and prepared by 
chemical synthesis. This new set of compounds was designed on the basis of 
the sequence of the Lead Peptide 1. Also this part of the work is not disclosed 
for the patent filing purposes. However, to better understand the re-design 
process after the screening of a simplified peptide library, an example is given 
in Scheme 1. 
The new series of compounds was named “II generation library”. As 
exemplified in the Scheme, each amino acid constituting the lead peptide 
sequence was replaced with the homologue amino acids, previously excluded 
from the first combinatorial library synthesis. Considering all possible amino 
acidic combinations, the lead peptide 1 and 24 new different peptides were 
synthesized and characterized by LC-MS analysis. In this new focused library, 
the hydrophobic tag and the molecular spacer were omitted to improve their 
solubility in solution. 
From the screening of this library, where peptides were tested at a single 42 
nM concentration, only peptides 8 and 24 disrupted the Gadd45β-MKK7 
interaction with an efficiency similar to that of the Lead Peptide 1, (panel Y, 
Fig. 1Y). The remaining 22 peptides did not exhibit any antagonistic effect. 
Considering the strong sequence conservation between the Lead Peptide 1 
and the other peptides, these results suggested a potent selectivity of the 
selected compounds. On the basis of its higher solubility, Peptide 8 was 
chosen as the best compound and was named Lead Peptide 2. To further 
validate this result, dose-dependent assays with Lead Peptides 1 and 2 and 
with a control peptide were carried out. The data are shown in Fig. 2Y. Again, 
these structures are not shown for the purpose of patent filing.  
The sequence of the Lead Peptide 1 and the Lead Peptide 2 are not disclosed 
in this work, as a patent covering the potential applications of these molecules 
is being filed, therefore any dissemination or presentation of data would be 
considered as “prior art” and would annul the main requirement of originality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme I: Redesigning active sequences after the screening of simplified 
peptide libraries. To complete the screening, taking into accounts the excluded 
residues, new sequences are re-designed by inserting homologous amino acids. In 
this scheme the redesign of sequences derived by a putative positive peptide has the 
sequence Asp-Gln-His-Leu. As shown, only 24 new peptides need to be prepared. 
 
 68 
 
Panel Y:  Screening the II generation focused library 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Y:  Selection of Lead Peptide 2 from the library of second generation.  
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Fig. 2Y: The concentration–dependent activity of Lead Peptides 1 and 2 has 
been compared to known antagonists by ELISA assay. 
The IC50 values extrapolated by non-linear fitting were: Lead Peptide 1: 1.3 
nM; Lead Peptide 2: 0.18 nM. 
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3.6.4 Validation of the combinatorial approach 
 
In literature are described only two antagonists of the Gadd45β-MKK7 
interaction (47) that are Gadd45β A60-D86 and MKK7 G132-N156. These two 
peptides were capable of disrupting the MKK7-Gadd45β binding because they 
mime the interface of protein-protein interaction. 
Our hypothesis is that tetrapeptide antagonists can be more efficient than long 
peptides, because they can have chemical and stechiometric characteristics 
comparable to those of small molecules.  
For this reason, the peptides mentioned above and the two Lead Compounds 
1 and 2, were tested in a dose-dependent Elisa competition. In this assay, 
every antagonist has shown a concentration–dependent activity (Panel Y Fig.  
2Y). According to our hypothesis tetrapeptides functioned better than the 
antagonist described in literature. In fact the Lead Peptide 1 and 2 exhibited 
an EC50 values of about 1.3nM and 0.18 nM respectively, while Gadd45β 
A60-D86 and MKK7 G132-N156 showed an EC50 values of about 21nM. 
These results suggest the high activity of two Lead Compounds identificated 
and confirm the technical efficiency of the combinatorial strategy. 
 
 
 
3.6.5 Lead peptides engineering 
 
The short half-life of peptides has been one of the major issues of peptide 
therapeutic. Peptides are typically cleared in the cell medium within minutes to 
hours after their administration. Therefore, to realize further characterization 
with some cell-based assays, the two Lead Peptides and one opportune 
negative control have been synthesized incorporating D-amino acids and 
tested again in Elisa assays. Their activity did not change. In this mode their 
stability has been substantially increased. 
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3.7 From combinatorial chemistry to validated hit: 
defining the mechanism of inhibition  
 
In addition to screening strategies based on synthetic tetrapeptide libraries, it 
became necessary to validate the results obtained using alternative 
assessments. The selected lead compounds were further characterized with 
different cell-based assay in order to confirm their antagonist activities. 
For this reason HA-Gadd45β was transiently co-expressed in HEK293T cells 
together with Flag-MKK7. Thus the intracellular localization of these proteins 
was assessed by immune-staining and further western blot, using properly 
antibodies (Fig. 1K). The interaction between Gadd45β and MKK7 was 
detected readily by immunoprecipitation of Flag-MKK7 and monitoring HA- 
Gadd45β co-precipitation.   
To support the idea that the selected antagonists are able to disrupt 
Gadd45β-MKK7 interaction, co-immunoprecipitation assays were carried out 
with and without peptidic inhibitors. As expected, incubating the 
immunocomplex with 1 and 5 nM of Lead Compounds 1 and 2, the HA-
Gadd45β co-immunoprecipitation decreased. Data shown in Fig. 2 K confirm 
the result previously observed throughout the deconvolution of combinatorial 
libraries. Indeed the Lead Peptides 1 and 2 exhibit a substantial activity at 
nanomolar concentration. 
 
3.7.1 Investigation of inhibition mechanism  
 
To investigate whether the Lead Peptides 1 and 2 were MKK7 inhibitors 
several kinase assays were performed. This way was addressed by using 
HEK293 cells transiently transfected with Flag-tagged MKK7. The kinase 
activation was realized by stimulation either with TNFα or with P/I. The kinase 
assays confirmed that MKK7 was efficiently activated (Fig. 1L).  In order to 
understand the level at which Gadd45β inhibits the JNK phosphorilation, 
another Kinase assay was carried out using the recombinant GST-Gadd45β 
as MKK7 competitor (Fig. 2L). After setting the best conditions of Gadd45β 
inhibitory activity at 5 µM, Lead Peptides 1 and 2 and the opportune negative 
controls were finally tested. 
Consistently with preliminary results, only the Lead Peptides 1 and 2 were 
able to prevent the MKK7-Gadd45β interaction. The results shown in Panel L 
suggest that they are active respectively in the range of concentration 1-5 nM 
and 0,5-1 nM (Fig. 3L). In vitro kinase assays established that their antagonist 
activity matched perfectly with the IC50 value detected by Elisa fitting (see 
Panel Y, Fig. 2Y). 
Additionally, the results previously described also suggested that the selected 
peptides disrupt the interaction between Gadd45β and MKK7 without 
interfering with the kinase activity directly. In order to investigate this particular 
issue, kinase assays were performed using only the peptides without the 
recombinant GST-Gadd45β protein. 
The results revealed that both lead compounds do not block JNK 
phosphorilation acting as inhibitors ATP-no competitive (Panel 4K). Data 
obtained from in vitro studies on these inhibitors should generate interesting 
insight into the argument previously discussed. Actually, the vast majority of 
 71 
kinase inhibitors work overlapping the ATP binding pocket. This competitive 
behavior often determine undesirable effects cross-reacting against other 
kinases.  
“Specific inhibition by a non specific effect” is a provocative expression but 
could be applied to inhibitory effect of MAPK inhibitors. 
As mentioned above in the introduction section, the signaling module 
composed by MAPK is an integrated system that means interaction between 
the different pathways.  
Instead the lead compounds 1 and 2 have an activity non-ATP competitive. 
Therefore they have the potential of taking a leading role in development of 
new drug candidates having powerful Biotechnological applications.  
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Panel K:  Validation of results obtained by 
combinatorial approach with cell based assays   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1K: Gadd45β physically interacts with MKK7. 
Western Blot showing the co-expression of HA-Gadd45β and Flag-MKK7 in 
293 cells. Anti-Flag immunoprecipitates of lysates from 293 cells previously 
transfected with pcDNAFlag-MKK7 and pcDNAHA-Gadd45β using different 
ratios:  1:1 (line 1); 1:2 (line 2) and 1:5 (line 3). 
 
 
 
 
Fig. 2K: Immunoprecipitation followed by western blot, showing physical 
association between endogenous Gadd45β and MKK7 and the destruction of 
immunocomplex by Lead Peptides 1 and 2. 
 
 
Flag-MKK7
HA-Gadd4521
29
35
50
1        2         3
HA-Gadd45β
Flag-MKK7
1nM 1nM 1nM
Le
a
d 
Pe
pt
id
e
 
2
Ne
ga
tiv
e
 
c
o
n
tr
o
l
HA Gadd45β
Le
a
d 
Pe
pt
id
e
1
Le
a
d 
Pe
pt
id
e
 
2
Ne
ga
tiv
e
 
c
o
n
tr
o
l
Le
a
d 
Pe
pt
id
e
1
 73 
Panel L: Lead compounds 1 and 2 disrupt Gadd-MKK7 
interaction without blocking JNK phosphorilation 
 
 
 
 
 
Fig . 1L: MKK7 activation with P/I and TNFα was monitored by combined 
immunoprecipitation  (Resin anti Flag) and Kinase assay  
 
 
   
 
 
 
Fig. 2L: Kinase assays showing a specific inhibition of active Mkk7 by purified 
GST-Gadd45β in vitro. Flag-tagged kinase were immunoprecipitates from 293 
cells treated with P/I (30 min) and pre-incubated with the indicated 
concentrations of Gadd45β. 
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Fig. 3L: The ability of lead compounds 1 and 2 to disrupt the interaction 
between Gadd45β and Mkk7 has been confirming by kinase assays.  
 
 
 
 
 
 
 
 
Fig. 4L: Kinase assays confirming that lead peptides 1 and 2 are non – ATP 
competitive inhibitors.  
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Antagonists of Gadd45β – Mkk7: from combinatorial 
approach to new therapeutic components 
 
The relationship between the pathological processes of infection, 
inflammation and cancer is correlated to the role of the transcription factor NF-
κB in cellular homeostasis (24) 
Therefore studying NF-κB target genes makes it is possible to understand the 
molecular mechanisms of inflammation, of tumor growth and progression. 
Gadd45β is one of the anti-apoptotic regulators controlled by NF-κB in 
response to pro-inflammatory stimuli and genotoxic stress (43). 
Gadd45β exerts its functions by interacting with several partners such as MAP 
kinases (43;47;50)  and DNA clamp protein (52;76) . 
In particular the physical interaction between Gadd45β and MKK7 has been 
widely described as a molecular link between the NF-kB cytoprotective effects 
and the suppression of the signaling of JNK, one of the main MKK7 
substrates that strongly promotes apoptosis.  
In addition it has been reported that both Gadd45β and MKK7 are able to 
dimerize or to oligomerize. Therefore their mutual interaction and the 
interaction with other partners can be regulated by this event. Understanding 
this complex network of interactions and finding effective antagonists is 
therefore of preeminent importance for elucidating in details the fine balance 
between cell death and cell survival and to modulate cell homeostasis for 
therapeutic applications. 
 
Accordingly, this project has been focused on the structural and functional 
characterization of the Gadd45β-MKK7 complex and on the identification of 
compounds able to disrupt this interaction. In fact, developing molecules able 
to block the pro-survival action of NF-κB without significantly compromising 
the innate activation of the immune system is an effective way to suppress the 
proliferative effects induced by Gadd45β expression. 
The first part of this study was dedicated to a complete investigation of the 
Gadd45β homodimerization by spectroscopic and biochemical techniques. 
Since Gadd45 proteins have no enzymatic activity, the self association could 
be a regulative mechanism under both physiological and pathological 
conditions. 
Analyses by Size Exclusion Chromatography, circular dichroism and native 
gels unequivocally confirmed that Gadd45β exists in solution prevalently as a 
non covalent dimer. In agreement with previous findings, ELISA-like assays 
showed a 1:1 stechiometry for the Gadd45β self-binding, while in contrast to 
previous data on Gadd45α, Gadd45β is seemingly able to only form dimers.  
Importantly, the self-association dissociation constant was estimated to be 
about 100 nM, a value which is similar to the cellular concentration estimated  
for proteins of this family (64;77). This high similarity suggests that equilibrium 
between monomers and dimers can occur in the cytoplasm, where up- and 
down-regulation of the protein could be a way to finely modulate self-
association as well as other external interactions.  
Applying a method of limited proteolysis of the protein, separation of the 
resulting fragments and binding competition assays, we have identified the 
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regions of Gadd45β involved in the self-association as corresponding to the 
predicted helix 1 (H1) and helix 5 (H5) of the protein (61). 
With the help of a homology model of the Gadd45β dimmer, we have 
hypothesized that the dimerization region can form a four-helix bundle, where 
the contiguous disposition of H1 and H5 in one monomer creates a large 
hydrophilic surface interacting in an anti-parallel fashion with the 
corresponding helix of the other monomer. 
In particular residues Gln13, Thr14 and Glu21 on H1 and Glu140, Tyr137, 
Glu133 and His129 on H5 are involved in a network of intra-molecular polar 
interaction which stabilizes the structure of the complex. 
The formation of a compact dimer is supported by studies of chemical 
denaturation with both GndHCl and urea, where it is seen that the protein, in 
the presence of up to 1M denaturants persists in the dimeric form, whereas it 
unfolds after reaching higher concentrations (74).  
It has been recently reported the crystal structure of Gabb45γ, which reveals 
a fold comprising an αβα sandwich with a central five stranded mixed β-sheet 
with α-helices packed on either side, similarly to the predicted Gadd45β 
model. By inspection of the crystal packing, Gabb45γ is a dimer, where the 
interface is formed by a four–helix bundle with predominant hydrophobic 
interactions. Residues Ile76-Leu80 of helix α3 and residues Tyr44-Lys48 of 
helix α2 contribute the vast majority of the interactions. It is worth to be 
noticed that the dimerization interface is formed by residues that are highly 
conserved among isoforms (78). The different dimerization surface between 
the Gadd protein family points out how even if some roles are common 
among the three isoforms, others are isoform- and cell-type-specific. In this 
regard, it is interesting to note that the Thr79 in Gadd 45β is implicated in its 
interactions with MKK7. 
The predicted helix H4, being parallel to H1, virtually extends the interaction 
surface towards the protein Loop 2, but does not contribute to protein self-
association. On the contrary it is reportedly involved in the binding with MKK7 
(61).  
In agreement with previous reports (61), and in contrast with others (50;79), 
Gadd45β and MKK7 strongly interact in vitro, exhibiting a KD of about 13 nM. 
This value is about 8-fold lower than that estimated for Gadd45β self-
association, thus suggesting that the two proteins are also able to interact in 
the presence of monomeric Gadd45β. Consistently, the two proteins still 
strongly interact in the presence of both eH1 and eH5 that efficiently abrogate 
the Gadd45β dimerization.  
By characterizing the recombinant MKK7, we found that, in agreement with 
other reports (76;80), also the folded kinase is dimeric suggesting that the 
interaction between Gadd45β and MKK7 takes place in the context of a large 
complex comprising at least two Gadd45β and two kinase units 
(MKK7/Gadd45β:Gadd45β/MKK7).  
Integrating these findings with the literature data, Gadd45β appears to have a 
modular structure despite its small size. 
In fact while the N- and C-termini are involved in self association, the central 
region, residues A60-A114 and the large acidic patches, is committed to 
kinase binding and regulation and to the interaction with core histones (region 
72-124) (81). 
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The same sub-domains, however, have concomitantly a role in the recognition 
of other partners such as PCNA (56), which binds the terminal region 27-50 
and 127-150 of Gadd45α, and nucleophosmin (81), which interacts with the 
region 61-100, thereby regulating nuclear entry . Therefore, while dissociation 
of Gadd45 proteins would be required for interaction with PCNA, a key player 
of the DNA repair mechanism primarily regulated by Gadd45 proteins, it 
seems dispensable for binding to kinases, core histones and nucleophosmin.  
 
The biochemical analysis of Gadd45β-MKK7 complex provided a new 
context for dissecting the structure-activity relationship of this interaction. 
Given the crucial effect of Gadd45β-MKK7 interaction in NF-kB-mediated JNK 
activity suppression, the selection of antagonists becomes an attractive target 
for cancer prevention and therapy.   
In the literature only two antagonist of the Gadd45β-MKK7 complex have 
been described: the peptides Gadd45β A60-D86 and MKK7 G132-N156 (47). 
These peptides are capable of disrupting the Gadd45β-MKK7 binding 
because they mimic the interface of protein-protein interaction. 
To select antagonists of the Gadd45β-MKK7 interaction, a combinatorial 
chemistry approach has been followed. Synthesis and screening of random 
peptide libraries have been chosen to permit the rapid selection and 
optimization of leads to produce drug candidates.   
By this process, Lead Compounds 1 and 2 have been selected from 
deconvoluting of two generations of tetrapeptide libraries. These novel 
antagonists can disrupt very efficiently the interaction between Gadd45β and 
MKK7 at concentrations in the low nanomolar range. The high potency of 
these compounds is more evident when compared with their IC50 values of 
about 0.8 nM with the value of about 21 nM calculated for Gadd45β A60-D86 
and MKK7 G132-N156. Importantly, the final Lead Compounds selected have 
both a molecular weight below 500 Da and a potent inhibiting activity.  
Further investigations by co-immunoprecipitation and kinase assays have 
confirmed that the measured antagonistic activity matches perfectly with the 
IC50 values from ELISA data.  
Additionally, the results suggest that the selected peptides disrupt the 
interaction between Gadd45β and MKK7 without directly interfering with the 
kinase activity. Indeed several kinase assays have confirmed that both Lead 
Compounds do not block JNK phosphorylation, therefore they do not enter the 
kinase ATP binding site. 
Considering the paradoxal contest of kinase inhibitors, these in vitro studies 
can open interesting prospective. 
Actually, the vast majority of highly selective small compounds modulate the 
kinase activity overlapping the ATP binding pocket. 
This kind of inhibitors, because of the high homology in sequence and 
structure of catalytic kinase sites (41), usually show undesirable effects by 
cross-reacting against several other kinases (11;38;82).  
Consequently, non ATP-competitive small compounds, such as Lead 
Peptides 1 and 2, have the potential of becoming very useful new drug 
candidates, since the selective inhibition of NF-kB downstream targets, such 
as Gadd45β, could be a way to convert inflammation-driven tumor growth into 
inflammation–induced tumor suppression. 
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Future studies are required to translate these basic findings into deeper 
practice developing novel compounds. Indeed the potential of peptides as 
drug candidates is limited by their poor pharmacokinetic properties and by 
their difficulties to cross cell membranes. Several experiments will be carried 
out to establish the key pharmacokinetic characteristics of Lead compounds 
1 and 2 and to establish the effects of these antagonists on other NF-κB 
regulated pathways 
 
Programmed Cell Death
 
 
Gadd45β-Mkk7: critical molecular linker between NFKB citoprotective 
effect and JNK cascade suppression.  
Given the importance of this pathway both in inflammation-inducing 
oncogenesis and cancer chemioresistence, to develop antagonists targeting 
Gadd45β Mkk7 interaction should provide a new prospective for alternative 
cancer treatments. 
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6.  ABBREVIATION INDEX 
 
4-VP:  4- vinyl pyridine  
BSA: Bovine Serum Albumin  
CD: Circular Dichroism 
DMEM: Dulbecco’s Modified Eagle’s Medium 
DMF: N,N-dimethylformamide  
DTT: 1,4-Dithiothreitol 
ELISA: Enzyme-Linked Immunosorbent Assay 
ERK: Extracellular Signal-Regulated Kinase 
FACS: Fluorescence-Activated Cell Sorting  
FBS: Fetal Bovine Serum  
Fmoc:  9H-Fluoren-9-ylmethoxycarbonyl 
FPLC: Fast Protein Liquid Chromatography 
Gadd: Growth Arrest DNA Damage inducible 
GdnHCl: Guanidine Hydrochloride 
GFP: Green Fluorescent Protein  
HA tag: Hemagglutinin  (Epitope YPYDVPDYA) 
HEK: Human Epithelia Cells  
HPLC: High Performance Liquid Chromatography 
HRP: horseradish peroxidase  
IPTG: isopropyl-beta-D-thiogalactopyranoside 
JNK: Jun N-terminal Kinase 
LB: Luria-Bertani 
LC-MS: Liquid Chromatography-Mass Spectrometry 
LPS: Lipopolysaccharide 
MAPKs: Mitogen Activated Protein Kinase  
MKK: MAP Kinase Kinase 
NF-kB: Nuclear Factor-kB 
NHS: N-hydroxysuccinimide 
OD600: Optical Density at 600 nm 
OPD: ortophenyldiamine 
P/I : PMA/ ionomycin  
PBS: Phosphate Buffered Saline 
PCR: Polymerase Chain Reaction 
PDA: Photodiode Array 
PMA: Phorbol Myristate Acetate 
PMSF: Phenylmethylsulphonylfluoride (Inhibitor of Serine proteases) 
RP-HPLC: Reverse Phase-High Pressure Liquid Chromatography 
SAPK: Stress Activated Protein Kinase  
SPPS: Solid-Phase Peptide Synthesis  
TFA: Trifluoroacetic acid 
TIS:  triisopropylsilane 
TNF-α: Tumor Necrosis Factor-α 
Tris: Triisopropylsilane 
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Abstract 
Gadd45α, β, and γ proteins, also known as growth arrest and DNA damage-
inducible factors, exert a number of cellular functions, including cell cycle 
regulation and propagation of signals produced by a variety of cellular stimuli, 
maintaining genomic stability and apoptosis. Furthermore Gadd45β has been 
indicated as a major player in the endogenous NF-κB-mediated resistance to 
apoptosis in a variety of cell lines. In fibroblasts this mechanism involves the 
inactivation of MKK7, the upstream activator of JNK, by direct binding within 
the kinase ATP pocket. Based on a number of experimental data, the 
structures of Gadd45β and the Gadd45β-MKK7 complex have recently been 
predicted and data show that interactions are mediated by the acidic loop1 
and 2 and helices 3 and 4 of Gadd45β. Here we provide further evidence that 
Gadd45β is a prevailingly α-helical protein and that in solution it is able to 
form non covalent dimers but not higher order oligomers, contrarily to what 
reported for the homologous Gadd45α. We also show that the contact region 
between the two monomers is comprised of the predicted helices 1 (residues 
Q17-Q33) and 5 (residues K131-R146) of the protein which appear to be 
antiparallel and to form a large dimerization surface not involved in MKK7 
recognition. Data thus suggest the occurrence of a high molecular weight 
complex containing at least an MKK7-Gadd45β:Gadd45β-MKK7 tetrameric 
unit whose complexity could be further increased by the dimeric nature of the 
isolated MKK7.  
 
INTRODUCTION 
The gadd45 growth arrest and DNA damage-inducible family of genes, 
comprising gadd45a, gadd45b and gadd45g, encode for the corresponding 
Gadd45α, Gadd45β and Gadd45γ acidic proteins of about 18 kDa. They are 
ubiquitously expressed and exert the primary function of growth arrest and 
apoptosis induction in response to several genotoxic stresses thus 
contributing to cellular homeostasis1; 2; 3; 4; 5; 6. They have also been implicated 
in a variety of other cell functions such as DNA replication and repair7, cell 
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cycle regulation8, and, depending on cell type and cell metabolic state, also in 
cell survival4; 9; 10; 11; 12; 13; 14; 15; 16. This last property is seemingly mostly 
exhibited by Gadd45β which has been described as an NF-kB-inducible gene 
and as a prominent mediator of the NF-kB protective response to TNFα- and 
UV-induced apoptosis4; 11; 17. However this aspect is still controversial and 
several reports indicate Gadd45β as an effective pro-apoptotic factor, too5; 6; 
17
. The mechanisms by which Gadd45β can promote cell survival have been 
extensively investigated and it has been found that in MEFs and other cells, 
upon NF-kB induction, it provides selective JNK inactivation by inhibition of 
the upstream MKK71; 10; 18. In hematopoietic cells, instead, it blocks JNK 
activation by binding to MKK44; 19, and in B cells it is a critical mediator of the 
pro-survival activity of CD40 elicited in response to Fas stimulation9.  
 Since there is no reported enzymatic activity for the Gadd45 proteins, it 
is believed that they exert their functions interacting with protein partners. 
Indeed, other than MKK7 and MKK4, highly specific interactions with PCNA6; 
20; 21; 22
, cdc2 23, waf/p2124, cdk1/cyclinB125, MEKK426 and CRIF127 are 
involved in Gadd45 regulation of the cell cycle and the response to external 
cell stimuli. A further interaction with the protein nucleophosmin28 has been 
described for Gadd45α and it has been shown that this protein can work as a 
vehicle for nuclear import. However, at present it is unknown whether 
Gadd45β and Gadd45γ share a similar mechanism of nuclear translocation. 
Importantly, it has been reported that Gadd45 proteins are also able to homo- 
and hetero-dimerize or oligomerize and regions involved in self-association of 
Gadd45α have been investigated using overlapping synthetic peptides 
spanning the entire protein sequence29.  
 The primary sequences of Gadd45 proteins share an overall 70% 
homology (about 60% identity, See Fig. 1a) and all contain six cysteines, five 
of which (from the 2nd to the 6th) are located in highly conserved positions. 
 An unusually long stretch of glutamic and aspartic acid residues, only 
partially conserved within the Gadd45γ variant, can be found starting from 
position 60 of Gadd45α and Gadd45β. These residues have been described 
as having a key role in both cdc223 and MKK7 inhibition1; 10. However, the 3D 
structure of this important class of proteins is currently unknown and so far a 
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predicted model has been reported1 for Gadd45β (Fig. 1b, 1c) and its complex 
with MKK7. These structures, supported by various experimental evidences, 
present a central four-stranded β-sheet surrounded by 5 α-helices and, as 
expected for a nuclear protein, all cysteine residues are predicted to reside far 
from each other and thus in the reduced state1. The acidic stretch appears to 
be in a large loop interacting with several basic and polar residues within the 
kinase active site and it is part of the minimum region of Gadd45β needed to 
bind and block MKK7 activity (A60-D86 fragment). Other regions involving the 
putative helix 3 (H3), a second acidic loop and part of helix 4 (H4) harbour 
other key residues contacting MKK7.  
Following an approach of protein enzymatic fragmentation and HPLC 
fractionation, here we identify the regions of Gadd45β implicated in self-
association and confirm those involved in binding with MKK7. We also show 
that Gadd45β is unable to form higher order oligomers, as only dimers are 
detected using different methods. These studies extend our knowledge on 
Gadd45β properties and suggest that protein self-association can have a 
primary role in regulating its biological activity. 
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RESULTS 
Gadd45β purification 
Recombinant construct pGEX6P-GADD45β allowed expression of the protein 
as a GST-fusion product containing a highly specific cleavage site for 
PreScission Protease upstream of the Gadd45β protein. The applied 
overexpression system was quite efficient, producing more than 6 mg of 
highly purified protein from 1 L of induced culture under the previous reported 
conditions 1. The recombinant protein obtained after GST removal had the 
sequence reported in Fig. 1b and was used only for oligomerization studies. 
The protein was characterized by SDS-PAGE and LC-MS analysis 
determining the exact MW (MWExp/Theor: 18096.6±1.0/18096.1 Da). His6-
Gadd45β used in the ELISA assays was similarly obtained with high yields 
and purity. The MW of 19196.5 amu as determined by LC-MS was consistent 
with the protein sequence (MWtheorical: 19196.52 amu). The protein was 
efficiently derivatized with biotin as described in the Methods section. Protein 
derivatization was assessed by mass spectrometry showing that about 90% of 
the protein harboured one biotin molecule, while the remaining appeared 
underivatized (data not shown).  
 
Investigation of Gadd45β oligomerization by gel filtration and CD 
studies 
Since previous studies reported on the capacity of Gadd45 proteins to 
oligomerize29, we investigated this point by carrying out a gel filtration analysis 
in the presence and/or absence of DTT and by native electrophoresis 
experiments. Gel filtration analysis of protein aliquots at the concentration of 
5.0 µM, showed that, in absence of DTT, two peaks were eluted at column 
volumes corresponding to a dimeric and tetrameric protein, that is 36 kDa and 
72 kDa, respectively (Fig. 2a, 2c). Conversely, under reducing conditions, the 
tetramer peak disappeared (Fig. 2b), indicating that it was held together by 
disulfide bridges, whereas the dimer was associated also through strong non-
covalent interactions. The presence of protein dimers or oligomers was also 
investigated by native gels, observing in this case the dimer and the monomer 
(Fig. 2d). According to these data Gadd45β seemingly exists in solution 
prevalently as a dimeric protein, in partial equilibrium – under certain 
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conditions (the non-denaturing gel) – with the monomer. Indeed, no higher 
order oligomers have been detected by either techniques. 
The far-UV CD spectrum of Gadd45β (11x10-6 M) in aqueous solution 
showed two negative bands at 209 and 222 nm and a positive band at 195 
nm indicative of a high content of α-helical conformations (Fig. 3a), as 
previously reported1. Importantly, also the His6-Gadd45β, utilized in different 
assays exhibited a very similar CD spectrum (not shown). The occurrence of 
oligomers was also investigated by this technique by comparative analysis of 
protein solutions at different concentrations. No differences were detectable 
between CD curves recorded on protein solutions at concentrations ranging 
between 5.5 x 10-5 M and 5.5 x 10-6 M (not shown) suggesting that dilution, at 
least in the range of the explored concentrations, did not affect the protein 
global folding nor the quaternary structure. Therefore, no indications could be 
obtained on the actual monomer-dimer status of the protein by this 
experiment. A CD analysis of the dependence on denaturant concentration 
was also performed to further assess the protein structure stability or the 
capacity to eventually dissociate into monomers. Chemical denaturation data 
(Fig. 3b and 3c) showed that Gadd45β unfolds cooperatively at about 2.0 M 
GdnHCl and 3.0 M urea. This may indicate that electrostatic interactions, 
which are more efficiently weakened by GdnHCl than urea30, play an 
important role in stabilization of Gadd45β.  
Upon denaturant removal, the protein secondary structure was 
recovered (Fig. 3a), suggesting that denaturation, as well as the eventual 
dimer dissociation (assuming it occurs at high denaturant concentration) is a 
reversible event. Also thermal denaturation experiments were carried out to 
confirm these observations; a single transition was observed at about 46.5 °C, 
but, most importantly, after slow cooling back to 20 °C, the protein could not 
recover the original structure because of disulfide cross-linking (detected by 
SDS-PAGE under reducing and non-reducing conditions, not shown). In 
comparison to those of other globular proteins31 the melting temperature is 
quite low indicating that Gadd45β is not a thermodynamically stable protein, 
according to the predicted structure that exhibits large and flexible loops1. 
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Expression and purification of MKK7 
MKK7 was produced in bacteria as a soluble GST-MKK7 fusion product. 
About 7 mg/L of the fusion protein were obtained in typical fermentations. The 
protein was initially purified by standard GSTrap and on-column PreScission 
protease cleavage. The material recovered was further purified by gel filtration 
chromatography, obtaining a product more than 95% pure. The protein was 
characterized by SDS-PAGE and LC-MS analysis and the experimental MW 
was consistent with that expected (not shown). Protein identity was further 
confirmed by trypsin digestion and LC-MS/MS analysis of the resulting 
fragments (not shown). The folding of MKK7 was assessed by CD analysis 
observing, as expected1, a spectrum with a mixed α-β content (Fig. 4a). In 
Fig. 4b the determination of the oligomeric state of the protein by gel filtration 
analysis is reported: the protein appears as a dimer, exhibiting an apparent 
MW of about 90 kDa. Importantly, also the fusion protein GST-MKK7, used in 
several assays in this study, eluted from the gel filtration column as a dimer. 
 
Identification of regions of Gadd45β involved in auto-association 
In an attempt to determine the protein self association surface, we used 
Gadd45β fragments as competitors of the protein self-association in an 
ELISA-like assay (see below). For this purpose, protein digestion by several 
enzymes was considered, comparing enzyme efficacy and specificity other 
than the length and complexity of the obtainable peptides. Following this 
analysis, an extensive digestion of a protein aliquot was carried out with 
trypsin which resulted in complete digestion and formation of fragments of 
suitable length to ensure a complete coverage of the protein primary structure 
(See Table I). Upon RP-HPLC fractionation (13 fractions), Gadd45β peptides, 
identified by MW and MS/MS sequencing, were essentially distributed along 7 
main fractions, since fractions 1-5 contained no material and fraction 11 
contained only very small amounts (less than 4%) of fragment L46-R91. All 
identified trypsin fragments are reported in Table I along with a 
correspondence with the predicted Gadd45β secondary structure reported in 
1
. Fractions 6, 7, 8 ,9, 10, 12 and 13 contained relevant amounts of the protein 
fragments. Notably, fraction 6 only contained the C-terminal G147-R160 
peptide (unstructured); fraction 7 contained, in a 1:1 ratio, the fragments L36-
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K45 (part of β1 and part of α2) and L98-R115 (part of α4; most of loop 2); 
fraction 8 contained (in a 85:15 ratio), a major fraction of fragments S132-
R146 (87%, the central region of α5, hereafter H5 short) and the peptide 
D116-K131 (β4); fraction 9 contained, in a 75:25 ratio, the N-terminal 
polyhistidine tag and a minor fraction of the peptide S132-R146 (α5); fraction 
10 contained only the fragment M16-R32 (92%, the remaining being 
distributed along the contiguous fractions), corresponding to most of helix 1; 
fraction 12 and 13 contained the fragment L46-R91, corresponding to part of 
α2, β2, loop1, α3, and part of β3. The ELISA assay to monitor Gadd45β self-
association was carried out by coating the His6-protein on the surface of 
microtiter wells. Protein association was followed by adding increasing 
amounts of biotinylated His6-Gadd45β and detecting the bound protein by 
using HRP-STRV. As shown in Figure 5a, the protein efficiently associated in 
a dose-dependent way, reaching signal saturation at a nearly 1:1 (mol/mol) 
ratio, as expected by a dimeric complex. The concentration of His6-Gadd45β 
resulting in a 50% of maximum binding was around 100 nM and it was taken 
as an estimation of the dissociation constant of self-association. To identify 
the Gadd45β regions involved in protein dimerization binding competition 
assays were then carried out using peptide fragments derived from Gadd45β 
digestion. The assays were performed using an invariable 1:0.5 (mol/mol) 
ratio of coated/soluble His6-Gadd45β and a 2:1 (mol/mol) ratio of peptide 
competitor/soluble protein. Initially, the synthetic peptide Gadd45β(A60-D86) 
described in reference1 as the minimum Gadd45β region able to bind MKK7, 
inhibiting its kinase activity, together with the synthetic MKK7(G132-N156), 
described as recapitulating the full length MKK7 binding capacity10. Results 
are summarized in Fig. 5b, where a plot of representative data is reported. 
Gadd45β trypsin fractions from 1 to 5 and fraction 11 were not utilized. 
Fractions 6, 7, 12 and 13 which contained consistent amounts of protein 
fragments (see Table I) were essentially ineffective. In contrast, fractions 8 to 
10 interfered with the association. In particular, fraction 8 exhibited a nearly 
30% binding reduction, fraction 10, which virtually contained only fragment 
M16-R32 (see Table I) including most residues from the helix 1, decreased 
protein association to about 50%, whereas fraction 9, containing most 
residues of the tag and a minor part of fragment S132-R146, disrupted 
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Gadd45β self-association by 25%. Interestingly, the synthetic peptides 
Gadd45β(A60-D86) and MKK7(G132-N156), identified as forming the binding 
interface between Gadd45β and MKK71; 10, appeared totally ineffective in this 
assay (also discussed later). To refine the ELISA data, those fragments 
unable to disrupt Gadd45β-Gadd45β interaction were not considered; 
furthermore, on examination of the predicted Gadd45β 3D model, it was 
decided not to further investigate the fragment D116-K131, present in fraction 
8 at 15%, since it corresponds to the fourth β-strand which should be buried 
within the protein core and therefore virtually inaccessible to external 
interactions (Fig. 1c). Hence we decided to investigate regions M16-R32 and 
S132-R146 corresponding to the regions within the putative H1 and H5, 
respectively. Examining the protein model, (Fig. 1c) the peptides were 
opportunely designed by adding N- and C-terminal amino acids in order to 
complete the helices, hence the corresponding synthetic peptides, A12-R35 
(hereafter extended Helix 1, eH1) and A129-N148 (hereafter extended Helix 
5, eH5) were prepared by chemical synthesis and purified to homogeneity by 
RP-HPLC. The peptide R91-E104, corresponding to the extended predicted 
eH4, was also similarly prepared and utilized as a negative control. These 
peptides were then tested in the Gadd45β-Gadd45β competition assay, using 
the same protein-protein and protein-competitors ratios as described 
previously. As shown in the same Fig. 5b, eH1 and eH5 blocked the Gadd45β 
self association by 82% and 78%, respectively, supporting the hypothesis that 
these regions are strongly involved in the interaction. On the contrary, peptide 
R91-E104 (eH4), lying in the model in the close proximity of H1 (Fig. 1c), as 
well as peptides Gadd45β(A60-D86) and MKK7(G132-N156) and the full 
length kinase did not interfere with the protein homodimerization. A dose-
dependent competition assay carried out with eH1, eH5, the short H5, eH4 
and full length MKK7, further confirmed the properties of H1 and H5 and the 
inefficacy of H4 to abrogate dimerization (See Fig. 5c). As expected, the full 
length kinase (fused to GST) was unable to block the Gadd45β self-
association even at higher concentrations. Remarkably, the IC50 for these 
competitors were 100 nM for H1, 180 nM for the extended Helix 5 and only 
600 nM for the short H5, indicating that the full H5 was more than 3 times 
efficient in disrupting the protein self-association. These results might account 
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for the relatively weak inhibition exhibited by fractions 8 (30%) and 9 (25%) 
which only contained the shorter variant of the H5. To further investigate this 
point, the synthetic peptides reproducing eH1, eH5, the short H5 and the eH4 
were analyzed by CD. The analyses were carried out in both phosphate buffer 
and in the presence of 20% TFE to measure the relative propensity of 
peptides to adopt α-helical conformations. As reported in Fig. 6a-d, whereas 
eHelices 1, 4 and 5 adopted a partially folded structure in buffer and readily 
folded into α-helices upon TFE addition, the short H5 remained in the 
unfolded state even after addition of the structuring solvent, suggesting an 
intrinsic incapacity to form organized structures. Thus, increasing the length at 
the N- and C-termini of the putative H5 provided a 5-fold increase in potency 
that can be partially ascribed to the lack of any structure of shorter variant. 
To further extend our knowledge of the interaction between the two 
monomers, we developed an assay to monitor the binding between MKK7 
and Gadd45β. Indeed this interaction has been thoroughly investigated in 
previous works by pull-down assays utilizing several point-mutated variants of 
both proteins1; 10. As shown in Fig. 7a, the association between the two 
purified protein was very strong: a rough estimation of the KD, deduced by the 
Gadd45β concentration at half of the saturation signal, was about 13 nM. 
Noticeably, signal saturation was reached at an approximate 1:1 molar ratio, 
suggesting that one MKK7 molecule should be sufficient to bind to one 
molecule of Gadd45β. The competition experiment carried out using 42 nM 
MKK7, 21 nM Gadd45β and a twofold excess of competitors over the soluble 
protein, is reported in Fig. 7b. As shown, peptides corresponding to the 
putative extended Helices 1, 4 and 5, MKK7(G132-N156) and Gadd45β(A60-
D86) were utilized. Consistent with the notion that MKK7 proximity do not 
interfere with the Gadd45β dimerization, eH1 and eH5 do not affect the 
binding, whereas peptides Gadd45β(A60-D86) and MKK7(G132-N156), 
believed to form part of the interface between the two proteins, completely 
abolish the interaction. The peptide R91-E104 corresponding to the putative 
eH4 and containing two key residues (M95/Q96) involved in kinase 
recognition 1, also proved ineffective to antagonize the Gadd45β-kinase 
binding, at the used concentration. Instead, soluble GST-MKK7, as expected, 
totally abolished the binding. Thus, these results corroborate the view that the 
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Gadd45β-MKK7 interaction is essentially mediated by residues comprised 
within loop 1 and H3 (region A60-D86) 1, while other regions, such as H4, only 
partially contribute or may have only a structural role. 
 
Modelling of the Gadd45β homodimer 
To have a more detailed depiction of interactions occurring at the 
interface between the two monomers, we performed manual docking of the 
two units. Examining the Gadd45β model, H1 and H5 helices form a 
continuous surface and constitute a putative half of a four-helix bundle motif. 
On this basis, a number of Gadd45β homo-dimer models were constructed. 
Several relative orientations, both parallel and antiparallel, of the two 
monomers were tested in order to optimize both steric and electrostatic 
complementariness. An accurate analysis was then carried out to assess the 
effective stability and consistence of the resulting complexes, therefore each 
starting model underwent energy minimisation and then 200ps of molecular 
dynamics (MD) simulations in solution. The best model in terms of specific 
side-chains interactions is reported in Fig. 8a, 8B. The model suggests that 
the dimerization region can form a four-helix bundle in which H1 and H5 
helices of one monomer interact in an antiparallel fashion with the 
corresponding helices of the other monomer. This representation also shows 
how the proposed complex is stabilized by a network of intermolecular polar 
interactions involving Gln13, Thr14 and Glu21 on H1 and Glu140, Tyr137, 
Glu133 and His 129 on H5. The presence of Glu residues univocally 
determines the antiparallel orientation of the subunits, because in the parallel 
one these residues face each other, thus destabilizing the complex. 
Interestingly, a four-helix bundle search in the PDB reveals the occurrence of 
a homo-dimer stabilized by intermolecular polar interactions in which Glu 
residues interact with Tyr and His (PDB entry 1U7M), similarly to what 
observed in our Gadd45β dimer model. 
 100 
DISCUSSION 
Protein dimerization and oligomerization have been often associated with 
protein function. Indeed, auto-association can be seen as a way to mask-
unmask functional sites or, for example, to regulate protein degradation by 
making inaccessible regions otherwise marked for degradation32; 33. Protein 
self-association is therefore believed to be a regulative mechanism under both 
physiological and pathological conditions. 
For Gadd45 proteins, a family of intracellular and intranuclear acidic 
proteins, this mechanism has also been speculated, as, reportedly, they 
homo- and hetero-dimerize and oligomerize under a variety of conditions29; 
the oligomerization properties of Gadd45α have been previously investigated 
and it has been seen that the protein can form dimers and higher order 
oligomers also with Gadd45β and Gadd45γ29. Given the high number of 
molecular interactions they establish, a deeper knowledge of regions involved 
in self-association is of pre-eminent importance, as the occurrence of homo-
oligomerization can impair Gadd45 functions as well as strongly influencing 
hetero-interactions. 
To extend our knowledge on the properties of Gadd45 proteins, we 
have investigated whether Gadd45β can also dimerize-oligomerize and 
whether this ability can influence its interaction with MKK7, an important 
component of the MAP kinase cascade whose function in cellular apoptosis is 
regulated by Gadd45β itself10. As a first step, oligomerization was extensively 
investigated by gel filtration chromatography, CD and native gel analyses. Gel 
filtration experiments unequivocally showed that Gadd45β exists in solution as 
a non covalent dimer at a concentration of about 5 µM, a concentration 50-
fold higher than the estimated self-association KD (about 100 nM). Indeed, 
under reducing conditions, only a single sharp peak at the elution volume of 
the dimer (36 kDa) was detected. Consistently, by CD analysis, no structural 
changes were observed for protein concentrations between 5.5 x 10-6 M and 
5.5 x 10-5, that is 55-fold and 550-fold excess over the estimated KD, 
respectively. The ELISA-like assay utilized to determine the KD, also showed 
that the protein self-binding is saturated for protein:protein ratios higher than 
1:1 (mol/mol), suggesting, likewise, the occurrence of dimers only. In 
agreement with all these findings, the analysis on native gels revealed the 
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presence of the dimeric protein and some monomer, whereas no higher order 
oligomers were detected. Therefore, in contrast to previous data on Gadd45α, 
Gadd45β is seemingly able to only form dimers, that, under some conditions 
appear to be in equilibrium with monomers. Importantly, the self-association 
constant, estimated to be about 100 nM, is much lower than that estimated for 
Gadd45α (about 2.5 µM,29) and close to the cellular concentration estimated 
for proteins of this family (about 100 nM)29. This discrepancy, partly due to the 
differences in primary structure, can also be explained by the large 
differences of protein concentrations utilized in the two studies. Indeed, as the 
self-association is concentration-dependent, we can reasonably assume that 
higher order oligomers occur only at very high protein concentration, a 
condition that is not actually reflected within the cytoplasm and nucleus. 
Furthermore, the high similarity between the values of KD and cell 
concentration also suggest that an equilibrium between monomers and 
dimers can occur in the cytoplasm, where up- and down-regulation of the 
protein could be a way to finely modulate self-association as well as other 
external interactions. 
Following an approach of self-interaction competition with protein 
fragments derived from trypsin digestion, we identified two distinct Gadd45β 
sites involved in self-association which correspond to the predicted H1 and H5 
of the protein1. Remarkably, these findings partially agree with the previous 
report on Gadd45α, for which also an N-terminal and a C-terminal region have 
been described as being involved in self-association. However, whilst the C-
terminal site (129–165) is virtually overlapping with the predicted H5 of 
Gadd45β, the N-terminal site, identified with residues 33-6129 does not match 
H1 (see the sequence alignments in Figure 1). Rather, it overlaps with the 
Gadd45β sequence predicted as the β1-α2-β2 region (see reference1, and 
Fig. 1) that is somewhat downstream in the sequence. In the cited study, a 
large fragment of Gadd45α (residues 20-33) exactly matching the Gadd45β 
H1, has not been considered, therefore a further comparison between the two 
different variants is not possible. However, given the high sequence homology 
between the two proteins, especially in this part of the sequences, we cannot 
rule out an involvement of the missing fragment in Gadd45α auto-association. 
Noticeably, by looking at the Gadd45β model (see Fig. 1 and 8), H1 and H5 
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are disposed contiguously and arranged anti-parallel to each other, therefore 
they seemingly form a large hydrophilic surface that also includes the 
adjacent H4. This observation still supports the view that the protein is unable 
to form higher order complexes, as it rules out the presence of a second 
independent site required to allow the oligomerization to propagate. Moreover, 
it suggests that auto-association is likely to occur through this unique surface 
(not involving H4) that, when engaged by a second monomer, could lead to 
the formation of a compact dimeric structure devoid of further self-interaction 
sites. The formation of a compact dimer is supported by studies of chemical 
denaturation with both GndHCl and urea, whereby it is seen that the protein, 
in the presence of up to 1M denaturants persists in the dimeric form (not 
shown), whereas it unfolds after reaching higher concentrations. 
H4, being parallel to H1, virtually extends the interaction surface 
towards the protein Loop 2 (see Fig. 1), but does not contribute to protein self-
association. On the contrary it is reportedly involved in the binding with 
MKK71. In agreement with previous reports1, and in contrast with others4; 34, 
Gadd45β and MKK7 strongly interact in vitro, exhibiting a KD of about 13 nM. 
This value is about 8-fold lower than that estimated for Gadd45β self-
association, thus suggesting that the two proteins are also able to interact in 
the presence of monomeric Gadd45β. Consistently, the two proteins still 
strongly interact in the presence of both eH1 and eH5 (see Fig. 7b) that 
efficiently abrogate the Gadd45β dimerization. By characterizing the 
recombinant MKK7, we found that, in agreement with other reports35; 36, also 
the folded kinase is dimeric (see Fig. 4b), suggesting that the interaction 
between Gadd45β and MKK7 takes place in the context of a large complex 
comprising at least two Gadd45β and two kinase units 
(MKK7/Gadd45β:Gadd45β/MKK7). However, the occurrence of such a 
complex, opens the possibility that, under regimens of protein up-regulation, 
larger aggregates can originate, and indeed, preliminary attempts to detect 
this complex by gel filtration analysis have so far invariably shown the 
presence of high molecular weight non-covalent complexes (L.T., unpublished 
observations). 
Despite their small size, Gadd45 proteins appear now to have a 
modular structure. In fact, these and previous findings show that distinct 
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protein regions are involved in interactions with different partners. While the 
N- and C-termini are involved in self-association, it similarly appears that a 
central region, spanning residues A60-A114 and comprising the large acidic 
patches, is committed to kinase binding and regulation1; 10; 23, and to the 
interaction with Core histones (region 72-124)37. The same sub-domains, 
however, have concomitantly a role in the recognition of other partners such 
as PCNA6, which binds the terminal region 27-50 and 127-150 of Gadd45α, 
and nucleophosmin28, which interacts with the region 61-100 thereby 
regulating nuclear entry28. Therefore, while dissociation of Gadd45 proteins 
would be required for interaction with PCNA, a key player of the DNA repair 
mechanism primarily regulated by Gadd45 proteins, it seems dispensable for 
binding to kinases, Core histones and nucleophosmin. Importantly, all these 
proteins have a prevailing localization within cell nuclei, where protein 
concentration can be considerably higher than in the cytosol and thus self-
association needs to be a less disruptive event. Assuming that Gadd45α and 
Gadd45β have distinct capacities for self-association, this difference would 
also reflect different properties that could be even more evident at higher 
protein concentrations. In this instance, the control of protein overexpression 
and/or the capacity of more efficient translocation to sub-cellular 
compartments could be a further critical point that contributes to the different 
biological properties of the two protein variants.  
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EXPERIMENTAL PROCEDURES 
 
Materials 
Enzymes, TPCK-treated trypsin and other chemicals for buffer preparation 
were purchased from Sigma-Aldrich as well as urea and guanidinium 
hydrochloride (GdnHCl). pGEX-6P-1 expression vector, PreScission protease, 
ÅKTA FPLC and columns for affinity, size exclusion and ion exchange 
chromatography were from GE Healthcare, Uppsala, Sweden. pETM 
expression vectors were from EMBL, Heidelberg. Pfu DNA polymerase was 
purchased from Stratagene. Restriction enzymes BamHI and XhoI and T4 
DNA Ligase were from New England Biolabs, Germany. Perfect Protein 
Markers were from Novagen, whilst SeeBlue Prestained markers were from 
Invitrogen. Vivaspin 5 KDa cut-off PES vertical membrane concentrators 
where from Sartorius group, Milan. Non Fat Dry Milk (NFDM) was from 
BioRad. Solvents for RP-HPLC analysis were all from Romil, Dublin, Ireland. 
DNA coding for human Gadd45β and human MKK7 were previously 
described1; 10. For peptide synthesis, protected Nα-Fmoc-amino acid 
derivatives and coupling reagents were purchased from Inbios (Pozzuoli, 
Italy), Sequencing-grade Trypsin, DIEA, Rink amide MBHA resin and other 
chemicals were from Sigma-Aldrich (Milano, Italy). Other reagents and 
chemicals suppliers are indicated in the Methods section. 
Solid phase peptide syntheses were performed on a fully automated peptide 
synthesizer AAPTECH 348 ΩAdvanced Chemtech (Louisville, KY). 
Preparative RP-HPLC were carried out on a Shimadzu LC-8A, equipped with 
a SPD-M10 AV detector on a Phenomenex Luna-COMBI HTS C18
 
column 
(5×2.12 cm ID; 10 µm). LC-MS analysis were carried out on an LCQ DECA 
XP Ion Trap mass spectrometer (ThermoElectron, Milan, Italy) equipped with 
an OPTON ESI source, operating at 4.2 kV needle voltage and 320 °C and 
with a complete Surveyor HPLC system, comprising an MS pump, an 
autosampler and a photo diode array (PDA). Narrow bore 50x2 mm C18 
BioBasic LC-MS columns from ThermoElectron were used for these analysis. 
Other chemicals, instrumentations and columns are specified in the Methods 
section. All ELISA assays to screen the Gadd45β trypsin fractions were 
carried out using a complete system (Hamilton Robotics, Milano, Italy) 
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comprising a liquid handler, an automatic arm, a washer and an automated 
96-well and 384-well reader. 
 
Expression and purification of GADD45β in E.coli 
Human Gadd45β, hereafter Gadd45β, was expressed both as pGEX6P-
GADD45β as reported previously1, and with an N-terminal His6 tag using the 
vector pET28aGADD45β10; in the latter case recombinant protein expression 
was optimized in BL21(DE3) bacterial strain induced in the presence of 0.1 
mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 16h at 22°C. 20 0 mL 
pellet was re-suspended in 20 mL cold lysis buffer (25mM Tris, 500mM NaCl, 
10mM Imidazole, 1mM DTT, Triton 0.05%, pH 7.5) supplemented with 
protease inhibitor mixture A (1 mM PMSF, 1.0 µg/mL aprotinin, 1.0 µg/mL 
leupeptin, 1.0 µg/mL pepstatin, 1.0 mg/mL lysozime) and incubated at room 
temperature for 30 min. Cells were disrupted by sonication on ice with 10 
seconds on/off cycles for a total sonication time of 10 min on. After 
centrifugation at 15000 rpm for 30 min at 4°C, the supernatant was purified on 
a ÅKTA FPLC chromatography system using 1 mL HisTrap HP. The column 
was washed with lysis buffer without triton and bound protein was eluted 
using an imidazole gradient from 10 to 500 mM. Protein elution was monitored 
at 280 nm and the resulting fractions were analyzed by 15% SDS-PAGE 
electrophoresis. The eluted fractions were dialyzed against buffer A (50 mM 
Tris, 150 mM NaCl, 1mM DTT, 1mM EDTA, pH 7.0). MonoQ step, gel 
filtration, as well as LC-MS analysis were carried out as previously described1.  
Analysis of the protein by gel filtration was compared with a calibration 
obtained with marker proteins run on the column under the same conditions. 
Comparison of chromatograms in the presence and in absence of 1 mM DTT 
in the running buffer was carried out to show the presence of covalent 
oligomers. Gel filtration analyses were carried out on a Superdex 75 10/300 
GL column. 
 
Cloning, expression and purification of human MKK7 (1- 400), in E. coli. 
Human MKK7 (1-400), hereafter only MKK7, was expressed as a recombinant 
protein with an N-terminal GST-tag using the vector pGEx-6P1, allowing the 
expression of the protein as GST-fusion product containing a highly specific 
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cleavage site for PreScission Protease upstream of MKK710. The MKK7 cDNA 
was amplified by PCR using pGEX-2T-MKK7/JNKK2 as template. 
Recombinant protein expression was optimized in the bacterial strain 
BL21(DE3)TrxB, induced in the presence of 0.1 mM IPTG for 16h at 22°C. 
200 mL culture were resuspended into 20 mL of cold buffer A added of a 
protease inhibitor mixture A and incubated for 30 min at room temperature. 
Cells were disrupted by sonication on ice and the total lysate was then 
centrifugated at 15000 rpm for 30 min at 4°C. The r esulting supernatant was 
loaded onto a 1 mL GSTrap FF column equilibrated with 50 mM Tris, pH 8.0, 
500 mM NaCl and washed extensively until the absorbance at 280 nm 
reached the baseline. The protein was then eluted with 10 mM GSH dissolved 
in 50 mM Tris, pH 8.0. Purity was assessed by SDS-PAGE and LC-MS 
analysis. When required GST-MKK7 was on-column digested with 
PreScission protease using 160U/mL resin incubating at 4°C for 5 days; gel 
filtration analysis was carried out on digested MKK7 using a Superose 6 10/30 
(GE Healthcare) previously calibrated with Ovalbumin, 44 kDa; BSA, 66 kDa; 
Transferrin, 81 kDa; Catalase, 206 kDa; Ferritin, 460 kDa, using as running 
buffer 50 mM Tris, 150 mM NaCl, 1mM DTT, 1mM EDTA, pH 7.0. 
 
Trypsin digestion and peptide fractionation 
An aliquot of Gadd45β (1.0 mg; 0.052 µmol) was dissolved in 2.0 mL of 50 
mM Tris, 20 mM CaCl2, pH 8.0. TPCK-treated trypsin (Sigma) was added at a 
final 1:100 enzyme-substrate ratio and the reaction left to stand at 37°C under 
gentle agitation for 16 hours. A protein sample (0.5 µg) was then analyzed by 
LC-MS/MS to assess protein digestion using a BioBasic 30x2 mm ID C18 
column. The column was equilibrated at 200 µL/min with 5% CH3CN, 
0.05%TFA, then a gradient from 5% to 55% over 65 minutes was applied and 
monitored by both PDA and MS. The MS analysis was conducted by 
alternatively recording full mass spectra and data dependent mass analysis 
(DDA) to obtain sequence information from peptide fragmentation. The 
remaining protein sample was finally injected on a 250x4.6 mm ID C18 
column equilibrated at 1.5 mL/min flow rate with 5% CH3CN, 0.1%TFA, 
applying a gradient of CH3CN, 0.1% TFA from 5% to 55% over 65 minutes to 
elute the peptides; 13 fractions of 5 minutes each were collected from time 
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zero to time 65 minutes, and were subsequently analyzed as reported before 
(4 µL) by LC-MS/MS. Lyophilized fractions were stored at –80°C until use.  
 
Circular Dichroism (CD) 
CD spectra were recorded on a Jasco J-810 spectropolarimeter (JASCO 
Corp, Milan, Italy) equipped with a Peltier type temperature control system 
according to a procedure previously reported1 and native Gadd45β was 
diluted in water to obtain a 5.5x10-5 M final concentration. A blank run was 
always carried out before every experiment and subtracted from the protein 
CD spectra. Chemically-induced denaturation was carried out on native 
Gadd45β performing 1°C increments every 2 min from 20°C to  80°C, 
monitoring CD signal at 222 nm. The temperature was then returned to 20°C 
to investigate an eventual refolding capacity of the thermally denatured 
protein. CD spectra were again collected after each 2 degrees. To investigate 
the effects of concentration on protein oligomerization, serially diluted 
solutions at concentrations ranging from 5.5x10-5 M to 5.5x10-6 M were 
analyzed using cuvettes with increasing path lengths in order to compensate 
the signal loss due to dilution. Chemical denaturation experiments were 
carried out evaluating the effect of urea and GdnHCl on Gadd45β 
denaturation as reported recently30. Briefly, pH controlled solutions with 
different concentrations of urea and GdnHCl, with constant protein 
concentration (5.5x10-5 M), were prepared and incubated for 16 h at 20°C. 
Chemical-induced denaturation was monitored by recording the CD value at 
222 nm for each sample. The reversibility of the denaturation was controlled 
after removal of denaturants from the unfolded protein sample by overnight 
dialysis. The capacity of the recovered protein to recognize MKK7 was also 
evaluated by direct ELISA binding. Corresponding blanks were always 
recorded and subtracted. CD spectra were registered at 25°C. CD analysis 
was also carried on the synthetic peptides used in the ELISA assays. 
Peptides concentrations were kept at 1.0x10-5 M and analyzed in a 0.1 cm-
path length quartz cuvette. Spectra were acquired in a 10 mM phosphate 
buffer at pH 7.0 and also in the presence of increasing concentration of TFE, 
up to 20% v/v. 
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Non-denaturing gels analysis 
Laemmli discontinuing system without SDS was used for non-denaturing gel 
separations. Protein mobilities of proteins were determined on gels at 8, 10, 
12 and 15% of bis-acrylamide, by loading 18 µg of protein from a 1.8 mg/mL 
solution (100 µM). Calibration markers were from Sigma-Aldrich and 
calibration curves were obtained as reported in reference38 and in the Sigma 
protocol, technical bulletin No. MKR-137.  
 
Peptide synthesis and purification 
Peptides corresponding to different regions of Gadd45β and MKK7 were 
designed on the basis of a predicted model38, and prepared by solid phase 
peptide synthesis as C-terminally amidated and N-terminally acetylated 
derivatives following standard Fmoc chemistry protocols. A Rink-amide MBHA 
resin (substitution 1.1 mmol/g) and aminoacid derivatives with standard 
protections were used in all syntheses. Cleavage from the solid support, 
performed by treatment with a trifluoroacetic acid (TFA)/triisopropylsilane 
(TIS)/water (90:5:5, v/v/v) mixture for 90 min at room temperature, afforded 
the crude peptides that were precipitated in cold ether, dissolved in a 
water/acetonitrile (1:1, v/v) mixture and lyophilized. Products were purified by 
RP-HPLC using a C18 Jupiter column (50x22 mm) applying a linear gradient 
of 0.1% TFA acetonitrile in 0.1% TFA water from 5% to 70% over 30 minutes. 
Peptide purity and integrity were confirmed by LC-MS mass measurements 
using a Surveyor LC system and coupled to an LCQ Deca XP mass 
spectrometer equipped with an OPTON ESI source. Characterizations were 
conducted under standard conditions of peptide analysis. Peptides were 
designed on the basis of the predicted Gadd45β secondary structure 
described in reference 1 and corresponded to extended Helix1, Helix 4, Helix 
5 short, and Helix 5, respectively (hereafter eH1: A12-R35, sequence: 
AAQKMQTVTAAVEELLVAAQRQDR; eH4: R91-E104, sequence: 
RVSGMQRLAQLLGE; H5 short, S132-R146 sequence: 
SHGLVEVASYCEESR; eH5, A129-N148, sequence: 
AWKSHGLVEVASYCEESRGN. The peptide 
GPVWKMRFRKTGHVIAVKQMRRSGN, corresponding to fragment G132-
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N156 of MKK710 and the fragment A60-D86 of Gadd45β (sequence: 
AIDEEEEDDIALQIHFTLIQSFCCDND), corresponding to the shortest region 
of Gadd45β still able to bind to and block MKK71 were also prepared and 
purified. The highly acidic peptide Gadd45β (A60-D86) was purified by RP-
HPLC using a C18 Jupiter column (50x22 mm) applying a linear gradient of 
pure acetonitrile over 10 mM phosphate buffer pH 7.0, from 5% to 70% over 
30 minutes. 
 
Biotinylation of Gadd45β 
Fractions of Gadd45β (1mg/ml) were biotinylated using an EZ Link NHS-LC-
biotin (Pierce) according to manufacturer’s instructions with slight 
modifications: 1 volume of NHS-LC-biotin 2 mg/mL was added to 20 volumes 
of protein and incubated 1 hour on ice; the reaction was then stopped by 
addition of 1 volume of 50 mM glycine. Biotinylated samples were dialyzed 
against buffer B (25 mM Tris, 150 mM NaCl 1 mM EDTA, 1 mM DTT, pH 7.5) 
to remove excess of glycine and free biotin and stored as working aliquots at -
80°C. The incorporation of 1-2 biotin per molecule of protein was recorded  by 
LC-MS analysis. 
 
Gadd45β self-association and competition ELISA assays 
To monitor Gadd45β dimerization, an ELISA-like assay was carried out. For 
this purpose Gadd45β at concentration of 0.52 µM in buffer B was dispensed 
into a 96 well microtiter plate. Some wells were filled with the buffer alone and 
were used as blanks. After 16 h incubation at 4°C t he solutions were removed 
and the wells filled with 350 µL of a 1% w/v solution of NFDM in 1x PBS 
(Phosphate-Buffered Saline) buffer. The plate was left to incubate for 1h at 
37°C in the dark. After washing with buffer T-PBS ( PBS with 0.004% added 
Tween), wells were filled with 100µL of biotinylated Gadd45β at 
concentrations ranging between 16 µM and 2.1 µM. Each data point was 
performed in triplicate. Following 1h incubation in the dark at 37°C the 
solutions were removed and the wells again washed with T-PBS. To each well 
100 µL of 1:1000 HRP-conjugated streptavidine (HRP-STRV) dissolved in 
buffer were added and the plate left to incubate for 1 h at 37°C in the dark. 
After removal of the enzyme solution and washing, 100 µL of the chromogenic 
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substrate OPD (o-phenylendiamine) 0.4 mg/mL in 50 mM phosphate-citrate 
buffer, containing 0.4 mg/mL urea-hydrogen peroxide were added and the 
colour was allowed to develop in the dark for 5 minutes. The reaction was 
stopped by adding 50 µL of 2.5 M H2SO4. The absorbance at 490 nm was 
read in all wells and the values were properly averaged subtracting the 
corresponding blank lines. For the competition experiments, 100 µL aliquots 
of His6-Gadd45β at 0.52 µM were coated on the wells of a microtiter plates 
and 0.26 µM biotinylated His6-Gadd45β (1:0.5 mol/mol ratio) was used 
throughout (pre-saturation condition). 0.52 µM peptides used as competitors 
were utilized at a 1:1 mol/mol ratio to coated unbiotinylated protein and pre-
incubated with 0.26 µM biotinylated Gadd45β for 30 minutes at 4°C prior to 
addition to each well. Peptides derived from the trypsin digestion were used at 
a nominal concentration of 0.52 µM, calculated assuming a 100% trypsin 
cleavage and a 100% recovery from the HPLC fractionation. GST-MKK7, 
Gadd45β eHelices 1, 4, 5 and the synthetic peptides MKK7(G132-N156) and 
Gadd45β(A60-D86), were always used at 0.52 µM. ELISA assays were 
carried out at least twice. Competition results are reported as (B/B0)X100, 
where B means the average OD from the triplicate data points for a given 
analyte and B0 is the average OD determined without competitor. 
 
Dose dependent competition assay 
Dose dependent competition assays were carried out to monitor the Gadd45β 
region of dimerization. For this purpose, 100 µl of 0.26 µM Gadd45β in buffer 
B was coated over night at 4°C on microtiter wells.  After 1 hour blocking with 
NFDM and TPBS washing, increasing concentration of competitors (Gadd45β 
(A12-R35), Gadd45β (R91-E104), Gadd45β (A129-N148), MKK7(G132-N156) 
and the whole kinase protein GST-MKK7 ranging from 0 to 0.52 µM were pre-
incubated with 0.13 µM biotinylated Gadd45β for 30 minutes prior to addition 
to each well. The subsequent steps of  ELISA assays were carried out  as 
previously described. 
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Gadd45β -MKK7 association 
Association between Gadd45β and MKK7 was investigated by ELISA assays 
by coating the GST-fused full length kinase for 16 h at 4°C, at a 
concentrations of 42 nM. After extensive washing with T-PBS buffer and 
NFDM blocking (1h, 37°C, 350 µL), wells were incuba ted with different 
solutions of biotinylated Gadd45β at concentrations ranging from 8.4 nM to 
168 nM. Bound protein was then detected as described previously. KD values 
were estimated as the concentration of Gadd45β able to give half of the 
saturation signal. Binding competition assays were performed by coating 
GST-MKK7 at 42 nM as described, a concentration of biotinylated Gadd45β of 
21 nM (pre-saturation conditions) and using the competitors (synthetic eH1, 
eH5, H5 short, eH4, Gadd45β(A60-D86), MKK7(G132-N156) and GST-
MKK7) at a 2:1 competitor:soluble protein ratio (concentration of competitors 
42 nM). 
 
Modelling of Gadd45β homo-dimers 
The model building procedure for Gadd45β protein was described in details in 
a previous work 1. To build Gadd45β homo-dimers, the first ten residues of 
the unstructured N-terminal region were removed. The resulting models 
obtained from manual docking were completed by addition of all hydrogen 
atoms and underwent energy minimisation with NAMD39 package using 
Charmm22 force field40. Molecular dynamics simulations were run in solvent 
by confining the minimized complexes in rectangular TIP3P water boxes, with 
a minimal distance from the solute to the box wall of 1.2 nm. Counterions 
(Na+) were added to neutralize the system. Particle mesh Ewald method was 
applied to calculate long-range electrostatics interactions, setting to 14 Å the 
non-bonded cutoff. The solvated molecules were then energy minimized 
through 1000 steps with solute atoms restrained to their starting positions 
using a force constant of 1 kcal mol-1Å-1 prior to molecular dynamics (MD) 
simulations. After this, the molecules were submitted to 50 ps restrained MD 
(1 kcal mol-1Å-1) at constant volume, gradually heating to 310 K, followed by 
50 ps restrained MD (1 kcal mol-1Å-1) at constant pressure to adjust system 
density. Production runs were carried out for 200 ps using a timestep of 1 fs. 
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Snapshots from production run were saved every 1000 steps and analyzed 
with NAMD program. Model figures were made with MOLMOL program41. 
 
 
Fraction Gadd45β 
tryptic 
peptides 
Relative 
distribution of 
fragments within 
fractions (%) 
Relative 
composition of 
the fraction (%) 
Predicted secondary 
structure* 
 
6 G147-R160 98 100 Unstructured 
7 L36-K45 
L98-R115 
98 
99 
50 
50 
Part of β1, part of α2  
Part of α4; most of 
loop 2 
8 S132-R146 
D116-K131 
87 
99 
85 
15 
α5 
β4 
9 -13-15  
S132-R146 
100 
5 
75 
25 
Tag 
α5  
10 M16-R32 92 95 α1 
12 L46-R91 10 100 Part α2, β2, loop1, α3, 
part β3 
13 L46-R91 87 100 Part α2, β2, loop1, α3, 
part β3 
 
 
Table I: Tryptic Gadd45β peptidic fragments as identified by LC-MS/MS analysis. 
Fragments less than 5% were not considered. Relative distributions of fragments in 
column 3 were calculated by comparing area integration of extracted ion peaks from a 
given fragment taken from the different fractions. The relative composition within each 
fraction was derived by comparing area integrations of extracted ion peaks of all the 
fraction components. *As reported in reference1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
sp|O75293|GA45B_HUMAN      MTLEELVACDNA---AQKMQTVTAAVEELLVAAQRQDRLTVGVYESAKLM 
sp|P24522|GA45A_HUMAN      MTLEEFSAGEQK---TERMDKVGDALEEVLSKALSQRTITVGVYEAAKLL 
sp|O95257|GA45G_HUMAN      MTLEEVRGQDTVPESTARMQGAGKALHELLLSAQRQGCLTAGVYESAKVL 
                           *****. . :     : :*: .  *:.*:*  *  *  :*.****:**:: 
sp|O75293|GA45B_HUMAN      NVDPDSVVLCLLAIDEEEEDDIALQIHFTLIQSFCCDNDINIVRVSGMQR 
sp|P24522|GA45A_HUMAN      NVDPDNVVLCLLAADEDDDRDVALQIHFTLIQAFCCENDINILRVSNPGR 
sp|O95257|GA45G_HUMAN      NVDPDNVTFCVLAAGEEDEGDIALQIHFTLIQAFCCENDIDIVRVGDVQR 
                           *****.*.:*:** .*::: *:**********:***:***:*:**..  * 
sp|O75293|GA45B_HUMAN      LAQLLG-----EPAETQGTTEARDLHCLLVTNPHTDAWKSHGLVEVASYC 
sp|P24522|GA45A_HUMAN      LAELLLLETDAGPAASEGAEQPPDLHCVLVTNPHSSQWKDPALSQLICFC 
sp|O95257|GA45G_HUMAN      LAAIVG--------AGEEAGAPGDLHCILISNPNEDAWKDPALEKLSLFC 
                           ** ::           : :  . ****:*::**: . **. .* ::  :* 
sp|O75293|GA45B_HUMAN      EESRGNNQWVPYISLQER 
sp|P24522|GA45A_HUMAN      RESRYMDQWVPVINLPER 
sp|O95257|GA45G_HUMAN      EESRSVNDWVPSITLPE- 
                           .***  ::*** *.* *  
GPLGS-TLEELVACDNAAQKMQTVTAAVEELLVAAQRQDRLTVGVYESAKLMNVDPDSVVLCLLAIDEEEEDDIALQIHFTLIQS
FCCDNDINIVRVSGMQRLAQLLGEPAETQGTTEARDLHCLLVTNPHTDAWKSHGLVEVASYCEESRGNNQWVPYISLQER  
Theoretical MW: 18098.30 Da
α1 α2 α3
α3
β1 β2
β3 β4
Loop 1
Loop 2 Loop 3α4 α5
unstructured
unstructured
(a)
(b)
(c)
 
 
Figure 1. a. Alignment of Gadd45α, β and γ sequences. An identity of about 60% is observed. 
Most differences are present in the region corresponding to the second acidic loop, with a 
Gadd45γ pentapeptide stretch remaining unpaired with the other two sequences. To correctly 
align the Gadd45α variant, an 8-residue long stretch is required. Within the acidic loop 1, 
residues Asp67 of Gadd45β is mutated to Arg in the α variant and to Gly in Gadd45γ. Regions 
involved in self-association are underlined. In b, a representation of the protein secondary 
structure is schematized based on the model described in reference1. c: Ribbon 
representation of Gadd45β three-dimensional model, colored by residue type according to the 
following scheme: hydrophobic residues in white, polar residues in yellow, acidic residues in 
red and basic residues in blue, histidine residues in cyan, tyrosine residues in pink. 
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Figure 2. Characterization of the oligomeric state of Gadd45β. a: Gel filtration analysis on a 
Superdex 75 10/30 of the recombinant protein under non reducing conditions. Two peaks at 
elution volumes compatible with dimeric and tetrameric forms are detected. In b, the same 
analysis carried out after addition of 1 mM DTT in the running buffer. The peak at lower 
elution volumes disappears, suggesting that it is due to covalent disulfide bridges. In c, the 
calibration curve utilized to determine the relative MW is reported. Cytochrome C, 12.4 kDa; 
RNase A, 14.7 kDa; Chymotrypsinogen, 25.0 kDa; Carbonic anhydrase, 29.0 kDa; 
Ovalbumin, 44.0 kDa; BSA, 66.0 kDa. All determinations have been determined at least twice. 
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d: Non-denaturing polyacrylamide gel analysis of Gadd45β at a concentration of 1.8 mg/mL 
(100 µM). 
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Figure 3. Circular dichroism characterization of the recombinant Gadd45β. a. CD spectra of 
the recombinant protein before and after denaturation with guanidinium and urea are 
reported. The protein appears to properly refold after the chemical treatment. Spectra at 7.5 
M urea and guanidinium (dotted lines) are also reported. Curves of chemical denaturation are 
representative of at least two independent experiments. CD curves have been obtained by 
averaging at least three consecutive acquisitions. CD curves of denatured Gadd45B are 
missing below 215 nm since CD signals are suppressed by the high concentrations of urea 
and guanidinium. In b Chemical denaturation by GuHCl. The protein unfolds in a cooperative 
way at guanidinium concentrations higher than about 2.5 M (See also Figure 3a). In c, the 
chemical denaturation by urea is also reported. Also in this case the protein unfolds 
cooperatively. Complete denaturation occurs at concentrations higher than about 4.0 M. 
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Figure 4. Recombinant human MKK7 is properly folded and appears to be dimeric. a. CD 
spectrum in the near UV of the protein showing that it adopts a prevailingly alpha helical 
conformation, as expected on the basis of the model proposed in reference 7. b. Calibration 
curve used to determine the apparent MW of the recombinant protein by gel filtration analysis. 
Ovalbumin, 44 kDa; BSA, 66 kDa; Transferrin, 81 kDa; Catalase, 206 kDa; Ferritin, 460 kDa. 
The protein appears to be dimeric as previously reported35; 36. Consistently, GST-MKK7, used 
in several experiments in this work, is also dimeric. All determinations were carried out under 
the same conditions and repeated at least twice. 
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Figure 5. Gadd45β is able to self-associate, the interaction being disrupted by Gadd45β 
trypsin fragments. a. Dose-dependent binding of biotinylated Gadd45β to the plate-adsorbed 
protein: Gadd45β self associates with an estimated KD of about 100 nM, assumed as the 
concentration of Gadd45β resulting in 50% maximum binding29. Notably, the signal reaches 
saturation at a 1:1 protein ratio, suggesting the formation of dimers only. b: Competition assay 
of the Gadd45β self-association by the trypsin-generated protein fragments and by synthetic 
peptides designed to reproduce helices as predicted in the protein model 1. c Dose-
dependent inhibition of Gadd45β self-association by GST-MKK7 full length, eHelix 4 (residues 
91-104), eHelix 5 (residues 129-148), eHelix 1 (residues 12-35) and the Helix 5 short 
(residues 132-146). While the kinase and the eHelix 4 are not able to block the Gadd45β self-
association, peptides corresponding to eHelix 1 and eHelix 5, potently reduce the association. 
The Helix 5 short, derived by trypsin cleavage, is less effective than the entire eHelix 5. Data 
are representative of at least 3 independent experiments. 
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Figure 6. CD spectra of the synthetic peptides in neutral buffers and in the presence of 20% 
TFE. a-d: CD spectra of the synthetic eHelix 1 (a), eHelix 4 (b), eHelix 5 (c) and Helix 5 short 
(d) in phosphate buffer and in the presence of 20% TFE. As shown, the complete predicted 
helices have a good propensity to adopt an α-helical conformation, whereas the short Helix 5 
persists in a random conformation even after addition of the structuring agent. This different 
property is likely contributing to the reduced peptide capacity to block the MKK7-Gadd45β 
interaction. CD curves have been obtained by averaging at least three consecutive 
acquisitions. 
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Figure 7. Gadd45β and MKK7 strongly interact and their association is not influenced by 
Helix 1 or Helix 5. a: binding curve of the association between GST-MKK7 and Gadd45β. The 
estimated KD is 13 nM. b: binding competition of the MKK7- Gadd45β association by 
Gadd45β and MKK peptides. eHelix 1, eHelix 5, Helix 5 short and eHelix 4 cannot disrupt the 
binding, whereas Gadd45β [A60-D86] and MKK7 [G132-N156], corresponding to the interface 
between the two proteins, completely abolish the interaction. Also the GST-fused full length 
kinase abolishes the interaction as expected. Data are representative of at least 3 
independent experiments. 
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(a)
(b)
 
 
Figure  8. Two orthogonal views of Gadd45β homo-dimer three-dimensional model in ribbon 
representation, rotated around the horizontal axis of the figure(a, b). One monomer is colored 
in pink, the other in pale green. Helices H1 and H5 of each monomer are colored in magenta 
and dark green, respectively. Residues lying on these helices are shown in stick 
representation and colored according to the following scheme: hydrophobic residues in white, 
acidic residues in red, basic residues in blue, histidine in cyan and tyrosine in magenta. 
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